(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~May 1, ~~2022,~~2023, there were ~~35,690,210~~35,805,586 of the Registrant’s common shares, no par value, issued and outstanding.

The accompanying notes are an integral part of these consolidated financial statements.

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining estimated useful life. Amortization expense for patents and developed technologies is included in cost of revenue in the accompanying consolidated statements of operations. Amortization expense for customer relationships and definite-lived trademarks, trade names and other intangibles is included in operating expenses in the accompanying consolidated statements of operations. Amortization expense was as follows (in thousands):

9. Debt

Outstanding debt consisted of the following (in thousands):


	March 31,			December 31,
	2023			2022
Senior Credit Facilities – term loan	$	4,934		$	4,832
Less: unamortized debt issuance costs		(30	)		(32	)
Total current portion of long-term debt	$	4,904		$	4,800

Senior Credit Facilities – term loan	$	77,467		$	77,060
Senior Credit Facilities – revolving credit facility		345,590			358,413
Less: unamortized debt issuance costs		(4,522	)		(4,811	)
Total long-term debt	$	418,535		$	430,662

Total Senior Credit Facilities	$	423,439		$	435,462

1613

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

~~10. Debt~~

~~Debt consisted of the following (in thousands):~~

September 30,

December 31,

2022

2021

Senior Credit Facilities – term loan
$
4,399

$
5,126

Less: unamortized debt issuance costs

(33
)

(29
)
Total current portion of long-term debt
$
4,366

$
5,097

Senior Credit Facilities – term loan
$
71,260

$
86,879

Senior Credit Facilities – revolving credit facility

372,287

346,579

Less: unamortized debt issuance costs

(5,100
)

(4,097
)
Total long-term debt
$
438,447

$
429,361

Total Senior Credit Facilities
$
442,813

$
434,458

Senior Credit Facilities

On December 31, 2019, the Company entered into an amended and restated credit agreement (the “Third Amended and Restated Credit Agreement”) with existing lenders for an aggregate credit facility of $450.0 million, consisting of a $100.0 million U.S. dollar equivalent euro-denominated (approximately €90.2 million) 5-year term loan facility and a $350.0 million 5-year revolving credit facility (collectively, the “Senior Credit Facilities”). ~~The~~As amended, the Senior Credit Facilities mature in ~~December 2024~~March 2027 and include an uncommitted accordion option pursuant to which the commitments under the revolving credit facility may be increased by an additional $~~200.0~~350.0 million in aggregate, subject to certain customary conditions.

The outstanding principal balance under the term loan facility is payable in quarterly installments of €1.1 million beginning in March 2020, with the remaining balance due upon maturity. The Company may make additional principal payments at any time, which will reduce the next quarterly installment payment due. Borrowings under the revolving credit facility may be repaid at any time through March 2027. The Company made principal payments of €~~3.4~~1.1 million ($~~3.5~~1.2 million) towards its term loan and $~~34.3~~14.1 million towards its revolving credit facility during the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023.

On March 27, 2020, the Company entered into an amendment (the “First Amendment”) to the Third Amended and Restated Credit Agreement and exercised a portion of the uncommitted accordion option. The First Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $145.0 million, from $350.0 million to $495.0 million, and reset the uncommitted accordion option to $200.0 million for potential future expansion.

On October 5, 2021, the Company entered into an amendment (the “Fourth Amendment”) to the Third Amended and Restated Credit Agreement to exercise the accordion option. The Fourth Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $200.0 million, from $495.0 million to $695.0 million, and reset the uncommitted accordion option to $200.0 million for potential future expansion.

On March 10, 2022, the Company entered into an amendment (the “Fifth Amendment”) to the Third Amended and Restated Credit Agreement to extend the maturity date from December 31, 2024 to March 10, 2027, update the pricing grid, replace LIBOR with SOFR as the reference rate for U.S. dollar borrowings, and increase the uncommitted accordion option from $200 million to $350 million. In connection with the Fifth Amendment, the Company capitalized $2.5 million deferred financing costs and recorded a $0.6 million loss from the write-off of a portion of the unamortized deferred financing costs.

The Company is required to satisfy certain financial and non-financial covenants under the Third Amended and Restated Credit Agreement. The Third Amended and Restated Credit Agreement also contains customary events of default. The Company was in compliance with these covenants as of ~~September 30, 2022.~~March 31, 2023.

Liens

The Company’s obligations under the Senior Credit Facilities are secured, on a senior basis, by a lien on substantially all of the assets of Novanta Inc.

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~

Fair Value of Debt

As of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, the outstanding balance of the Company’s debt approximated its fair value based on current rates available to the Company for debt of similar maturities. The fair value of the Company’s debt is classified as Level 2 under the fair value hierarchy.

~~11.~~10. Leases

Most leases held by the Company expire between ~~2022~~2023 and 2036. In the U.K., where longer lease terms are more common, the Company has a land lease that extends through 2078. Certain leases include one or more options to renew, with renewal terms that can extend the lease term from one to 10 years, and options to terminate the leases within one year. The exercise of lease renewal or termination options is at the Company’s sole discretion; therefore, the majority of renewal options to extend the lease terms are not included in the Company’s right-of-use assets and operating lease liabilities as they are not reasonably certain of being exercised. The Company regularly evaluates the renewal options and includes the renewal periods in the lease term when they are reasonably certain of being exercised. The depreciable lives of the right-of-use assets and leasehold improvements are limited to the expected lease terms.

~~The following table summarizes the components of lease costs (in thousands):~~

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

2022

2021

2022

2021

Operating lease cost
$
2,544

$
2,418

$
7,936

$
6,213

Finance lease cost

Amortization of right-of-use assets

150

149

451

451

Interest on lease liabilities

77

85

234

257

Variable lease cost

271

275

888

834

Total lease cost
$
3,042

$
2,927

$
9,509

$
7,755

1814

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

The following table summarizes the components of lease costs (in thousands):


	Three Months Ended
	March 31,		April 1,
	2023		2022
Operating lease cost	$	2,638	$	2,744
Finance lease cost
Amortization of right-of-use assets		150		150
Interest on lease liabilities		71		79
Variable lease cost		236		265
Total lease cost	$	3,095	$	3,238

The following table provides additional details of balance sheet information related to the Company’s leases (in thousands, except lease term and discount rate):


	September 30,			December 31,			March 31,			December 31,
	2022			2021			2023			2022
Operating leases
Operating lease right-of-use assets	$	43,520		$	48,338		$	41,964		$	43,317

Current portion of operating lease liabilities	$	7,663		$	7,334		$	7,657		$	7,793
Operating lease liabilities		40,907			45,700			39,578			40,808
Total operating lease liabilities	$	48,570		$	53,034		$	47,235		$	48,601

Finance leases
Property, plant and equipment, gross	$	9,582		$	9,582		$	9,582		$	9,582
Accumulated depreciation		(5,520	)		(5,068	)		(5,821	)		(5,670	)
Finance lease assets included in property, plant and equipment, net	$	4,062		$	4,514		$	3,761		$	3,912

Accrued expenses and other current liabilities	$	651		$	599		$	684		$	668
Other liabilities		4,825			5,309			4,476			4,652
Total finance lease liabilities	$	5,476		$	5,908		$	5,160		$	5,320

Weighted-average remaining lease term (in years):
Operating leases		8.2			9.0			8.1			8.2
Finance leases		6.8			7.5			6.3			6.5
Weighted-average discount rate:
Operating leases		4.67	%		4.72	%		4.72	%		4.64	%
Finance leases		5.54	%		5.54	%		5.54	%		5.54	%

The following table provides additional details of cash flow information related to the Company’s leases (in thousands):

Nine Months Ended

September 30,

October 1,

2022

2021

Cash paid for amounts included in lease liabilities:

Operating cash flows from finance leases
$
234

$
257

Operating cash flows from operating leases
$
5,921

$
5,562

Financing cash flows from finance leases
$
447

$
9,166

Supplemental non-cash information:

Right-of-use assets obtained in exchange for new operating lease liabilities
$
4,621

$
15,340


	Three Months Ended
	March 31,		April 1,
	2023		2022
Cash paid for amounts included in lease liabilities:
Operating cash flows from finance leases	$	71	$	79
Operating cash flows from operating leases	$	1,988	$	1,985
Financing cash flows from finance leases	$	156	$	148
Supplemental non-cash information:
Right-of-use assets obtained in exchange for new operating lease liabilities	$	142	$	787

~~During the nine months ended October 1, 2021, the Company paid $8.7~~ million upon the exercise of an option to purchase a building under a finance lease agreement in Germany. The cash payment is presented as a cash outflow from financing activities in the consolidated statement of cash flows.

1915

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

Future minimum lease payments under operating and finance leases expiring subsequent to ~~September 30, 2022,~~March 31, 2023, including operating leases associated with facilities that have been vacated as a result of the Company’s restructuring actions, are summarized as follows (in thousands):


Year Ending December 31,	Operating Leases			Finance Leases			Operating Leases			Finance Leases
2022 (remainder of year)	$	2,434		$	243
2023		9,030			930
2023 (remainder of year)							$	6,954		$	710
2024		8,376			954			8,974			954
2025		8,013			954			8,413			954
2026		6,940			979			7,225			979
2027								6,366			1,003
Thereafter		25,347			2,506			20,537			1,505
Total minimum lease payments		60,140			6,566			58,469			6,105
Less: Interest		(11,570	)		(1,090	)		(11,234	)		(945	)
Present value of lease liabilities	$	48,570		$	5,476		$	47,235		$	5,160

~~12.~~11. Preferred and Common Shares and Share-Based Compensation

Preferred Shares

In May 2021, the Company’s shareholders approved a special resolution to amend the Company’s articles to authorize up to 7.0 million preferred shares for future issuance. The Company’s Board of Directors is authorized to designate and issue one or more series of preferred shares, fix the rights, preferences and designation, as deemed necessary or advisable, relating to the preferred shares, provided that no shares of any series may be entitled to more than one vote per share. As of ~~September 30, 2022,~~March 31, 2023, no preferred shares had been issued and outstanding.

Common Share Repurchases

~~In October 2018, the Company’s Board of Directors approved a share repurchase plan (the “2018 Repurchase Plan”), authorizing the repurchase of $25.0~~ ~~million worth of the Company’s common shares. During the three months ended July 1, 2022, the Company completed the 2018 Repurchase Plan and repurchased~~ 80 ~~thousand shares for an aggregate purchase price of $9.5~~ ~~million at an average price of $118.97~~ ~~per share. Since the inception of the 2018 Repurchase Plan, the Company has repurchased a cumulative total of~~ ~~264~~ ~~thousand shares for an aggregate purchase price of $25.0~~ ~~million at an average price of $94.57~~ ~~per share.~~

In February 2020, the Company’s Board of Directors approved a new share repurchase plan (the “2020 Repurchase Plan”), authorizing the repurchase of ~~an additional~~ $50.0 million worth of the Company’s common shares. During the three months ended July 1, 2022, the Company repurchased 4 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of $0.5 million atand an average price of $116.95 per ~~share under the 2020 Repurchase Plan.~~share. During the three months ended ~~September 30, 2022,~~March 31, 2023, the Company did not repurchase any shares. As of ~~September 30, 2022,~~March 31, 2023, the Company had $49.5 million available for future share repurchases under the 2020 Repurchase Plan.

Share-Based Compensation Expense

The table below summarizes share-based compensation expense recorded in the consolidated statements of operations (in thousands):

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

2022

2021

2022

2021

Selling, general and administrative
$
4,649

$
4,360

$
13,906

$
13,123

Research and development and engineering

586

534

1,780

1,776

Cost of revenue

719

631

2,123

2,305

Restructuring, acquisition, and related costs

—

2,965

—

2,965

Total share-based compensation expense
$
5,954

$
8,490

$
17,809

$
20,169

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~


	Three Months Ended
	March 31,		April 1,
	2023		2022
Selling, general and administrative	$	5,531	$	5,201
Research and development and engineering		443		700
Cost of revenue		492		873
Restructuring, acquisition, and related costs		—		—
Total share-based compensation expense	$	6,466	$	6,774

Share-based compensation expense reported in selling, general and administrative expenses included expenses related to restricted stock units and deferred stock units granted to the members of the Company’s Board of Directors of $~~1.1~~0.9 million and $~~1.1~~1.0 million during the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and April 1, 2022, ~~and October 1, 2021,~~ respectively.

Restricted Stock Units and Deferred Stock Units

The Company’s restricted stock units (“RSUs”) have generally been issued with vesting periods ranging from zero to five years and vest based solely on service conditions. Accordingly, the Company recognizes compensation expense on a straight-line basis

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2023

(Unaudited)

over the requisite service period. The Company reduces the compensation expense by an estimated forfeiture rate which is based on anticipated forfeitures and historical forfeiture experience.

Deferred stock units (“DSUs”) are granted to the members of the Company’s Board of Directors (the ~~"Board"~~“Board”). Compensation expense associated with the DSUs is recognized in full on the date of grant, as the DSUs are fully vested and non-forfeitable upon grant. Outstanding DSUs are converted into common shares upon Board members' resignation or retirement from the Board. ~~During the nine months ended September 30, 2022,~~ 52 ~~thousand shares of outstanding DSUs were converted into common shares upon the retirement or resignation of certain Board members.~~ There were 3841 thousand and 9138 thousand DSUs outstanding as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. Outstanding DSUs are included in the calculation of weighted average basic shares outstanding for the respective periods.

The table below summarizes activities relating to RSUs and DSUs issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the ~~nine~~three months ended ~~September 30, 2022:~~March 31, 2023:


	Shares (In thousands)			Weighted Average Grant Date Fair Value		Shares (In thousands)			Weighted Average Grant Date Fair Value
Unvested at December 31, 2021		292		$	115.42
Unvested at December 31, 2022							238		$	128.26
Granted		118		$	136.41		81		$	155.12
Vested		(135	)	$	114.12		(89	)	$	121.47
Forfeited		(13	)	$	126.79		(9	)	$	132.87
Unvested at September 30, 2022		262		$	124.72
Expected to vest as of September 30, 2022		242
Unvested at March 31, 2023							221		$	140.82
Expected to vest as of March 31, 2023							196

The total fair value of RSUs and DSUs that vested during the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 was $~~18.1~~13.8 million based on the market price of the underlying shares on the date of vesting.

Performance Stock Units

The Company typically grants ~~two types of performance-based stock awards, EPS-PSUs and TSR-PSUs, to certain members of the executive management team on an annual basis. Both types of~~ performance-based restricted stock ~~units~~unit awards (“PSUs”) that are based on the Company's financial metrics, market conditions, or a hybrid of financial metrics and market conditions. These performance stock unit awards generally cliff vest on the first day following the end of the ~~three-year~~specified performance period.

The number of common shares to be issued upon settlement following ~~the~~ vesting of ~~EPS-PSUs~~the Company's financial metrics attainment-based PSUs (“attainment-based PSUs”) is determined based on the Company’s ~~cumulative non-GAAP EPS~~financial metrics over ~~a three-year~~the specified performance period against the ~~performance~~ targets established by the Company’s Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the ~~three-year~~specified performance ~~cycle.~~period. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

The number of common shares to be issued upon settlement following ~~the~~ vesting of ~~TSR-PSUs~~the market condition-based PSUs (“market-based PSUs”) is determined based on the relative market performance of the Company’s common ~~shares~~stock compared to the Russell 2000 Index over a ~~three-year~~the specified performance period using a payout formula established by the Company’s Board of Directors at the time of grant and will be in the range of zero to 200% of the target number of shares. The Company recognizes the related compensation expense based on the fair value of the ~~TSR-PSUs,~~market-based PSUs, determined using the ~~Monte Carlo~~Monte-Carlo valuation ~~method~~model as of the grant date, on a straight-line basis from the grant date to the end of the ~~three-year~~specified performance period. Compensation expense on market-based PSUs will not be affected by the number of ~~TSR-PSUs~~shares that will ultimately vest at the end of the ~~three-year~~specified performance period.

21The number of common shares to be issued upon settlement following vesting of the PSU awards that are based on achievement of a hybrid of financial metrics and market conditions (“Hybrid PSUs”) is determined based on the Company's financial metrics achieved over the specified performance period against the targets established by the Company's Board of Directors at the time of grant with a market condition multiplier and will be in the range of zero to 260% of the target number of shares. The Company determines the fair value of the market condition multiplier using the Monte-Carlo valuation model as of the grant date. The Company recognizes compensation expense associated with the Hybrid PSUs ratably over the specified performance period based on the fair value of the PSUs as of the grant date and the number of shares expected to be earned. The probability assessment is

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

~~In January 2022, the Company granted ATI-PSUs to ATI employees. The number of common shares to be issued upon settlement following vesting is determined based on a performance matrix for a~~

~~four-year~~ ~~performance period against certain performance targets and will be in the range of~~ ~~zero~~ to ~~100~~% of the target number of shares. The Company recognizes compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the four-year performance cycle. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

The table below summarizes the activities relating to the performance-based awards issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the ~~nine~~three months ended ~~September 30, 2022:~~March 31, 2023:


	Shares (In thousands)			Weighted Average Grant Date Fair Value		Shares (In thousands)			Weighted Average Grant Date Fair Value
Unvested at December 31, 2021		162		$	122.26
Unvested at December 31, 2022							216		$	144.16
Granted		107		$	159.00		57		$	179.15
Performance adjustments(1)							20		$	122.24
Vested		(41	)	$	108.58		(70	)	$	116.56
Forfeited		(10	)	$	156.62		(7	)	$	167.06
Unvested at September 30, 2022		218		$	144.40
Expected to vest as of September 30, 2022		230
Unvested at March 31, 2023							216		$	160.81
Expected to vest as of March 31, 2023							241

(1) The amount shown represents performance adjustments related to the performance-based awards granted on February 20, 2020. These units vested at a blended payout of 142% during the three months ended March 31, 2023 based on the achievement of cumulative Non-GAAP EPS and applicable relative TSR performance conditions, respectively, over the performance period of fiscal years 2020 through 2022.

The unvested PSUs are shown at target payout levels in the table above. As of ~~September 30, 2022,~~March 31, 2023, the maximum number of common shares tothat could be earned under these PSU grants was approximately ~~343~~381 thousand shares.

The total fair value of PSUs that vested during the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 was $~~7.2~~9.9 million based on the market price of the underlying common shares on the date of vesting.

The grant-date fair value of the ~~TSR-PSUs at~~Hybrid PSUs granted during the ~~date of grant~~three months ended March 31, 2023 was estimated using the Monte Carlo valuation method with the following assumptions:


	Nine Months Ended September 30, 2022			Three Months Ended March 31, 2023
Grant-date stock price	$	137.29		$	156.72
Expected volatility		40.33	%		35.89	%
Risk-free interest rate		1.81	%		4.44	%
Expected annual dividend yield		—			—
Fair value	$	144.38		$	181.45

Stock Options

In February ~~2022,~~2023, the Company granted 4048 thousand nonqualified stock options to certain members of the executive management team to purchase common shares of the Company at a strike price equal to the closing market price ~~of the Company’s common shares~~ on the date of grant. The stock options vest ratably over a ~~three-year~~three years ~~period from~~on the anniversary of the date of grant and expire on the seventh anniversary of the date of grant. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recognizes compensation expense related to the stock options on a straight-line basis over the vesting period in the consolidated statement of operations.

2218

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

The table below summarizes the activities relating to stock options issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the ~~nine~~three months ended ~~September 30, 2022:~~March 31, 2023:

Shares
(In thousands)

Weighted
Average Exercise Price

Outstanding as of December 31, 2021

60

$
14.13

Granted

40

$
135.86

Exercised

—

$
—

Forfeited or expired

—

$
—

Outstanding as of September 30, 2022

100

$
62.77

Exercisable as of September 30, 2022

60

Expected to vest as of September 30, 2022

40




	Shares (In thousands)		Weighted Average Exercise Price
Outstanding as of December 31, 2022		84	$	72.18
Granted		48	$	135.86
Exercised		—	$	—
Forfeited or expired		—	$	—
Outstanding as of March 31, 2023		132	$	102.86
Exercisable as of March 31, 2023		57
Expected to vest as of March 31, 2023		75

The aggregate Black-Scholes fair value of $~~1.9~~3.0 million for the stock options granted during the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 was estimated using the following assumptions as of the grant date:


	~~Nine Months Ended September 30, 2022~~		Three Months Ended March 31, 2023
Expected option term in years		4.5
Expected volatility		~~39.3~~40.7	%
Risk-free interest rate		~~1.83~~4.00	%
Expected annual dividend yield		—

The expected option term was calculated using the simplified method permitted under Codification of Staff Accounting Bulletins Topic 14, “Share-Based Payment”. The expected volatility was determined based on the historical volatility of the Company’s common shares over the expected option term.~~Risk-free~~ The risk-free interest rate was based ~~upon~~on treasury instrument whose term was six months longer than the expected option term. The expected annual dividend yield is zero as the Company does not have plans to issue dividends.

~~13.~~12. Income Taxes

The Company determines its estimated annual effective tax rate at the end of each interim period based on full-year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in the period in which the changes are determined. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada’s statutory tax rate of 29.0% in the determination of the estimated annual effective tax rate.

The Company maintains a valuation allowance on balances of certain U.S. state net operating losses, credits and certain non-U.S. tax attributes that the Company has determined are not more likely than not to be realized. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized. In conjunction with the Company’s ongoing review of its actual results and anticipated future earnings, the Company continuously reassesses the possibility of adding a new or additional valuation allowance or releasing the valuation allowance currently in place on its deferred tax assets.

The ~~Company's~~Company’s effective tax rate of ~~16.0~~7.5% for the three months ended ~~September 30, 2022 differs from the Canadian statutory tax rate of~~ ~~29.0~~% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, and R&D tax credits, partially offset by disallowed compensation and uncertain tax position accruals.

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~

~~The Company's effective tax rate of~~ ~~13.8% for the nine months ended September 30, 2022~~March 31, 2023 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, R&D tax credits and windfall tax benefits upon vesting of certain share-based compensation awards, ~~during the period,~~ partially offset by disallowed compensation and uncertain tax position accruals. For the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the ~~windfall~~ tax benefits upon vesting of certain share-based compensation awards had a benefit of ~~0.2~~8.2% on the Company’s effective tax rate.

Beginning in January 2022, the Tax Cuts and Jobs Act of 2017 (“TCJA”) requires that research and development (“R&D”) expenditures be capitalized and amortized for income tax purposes over five years for domestic research and fifteen years for foreign research, rather than being deducted as incurred. This has the effect of increasing the Company’s cash taxes and deferred tax assets. Since January 2022, the Company has recognized deferred tax assets of $19

NOVANTA INC.~~9.2~~

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ~~million for the relevant R&D expenditures. This provision also has an indirect benefit of~~

AS OF MARCH 31, 2023~~3.8~~

(Unaudited)% on the Company’s effective tax rate for the nine months ended September 30, 2022, as the Company’s estimated Foreign Derived Intangible Income deduction has increased as a result of increased U.S. taxable income. The provision for income taxes for both the three months and the nine months ended September 30, 2022 reflects the impact of the TCJA.

The Company’s effective tax rate of (~~0.6~~9.1%) for the three months ended ~~October~~April 1, ~~2021~~2022 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, other tax credits, and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by ~~an increase in valuation allowances.~~

~~The Company’s effective tax rate of~~ ~~2.0% for the nine months ended October 1, 2021 differs from the Canadian statutory tax rate of~~ ~~29.0~~% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, other tax credits, a release ofdisallowed compensation and uncertain tax position reserves, and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by the revaluation of long term deferred tax balances resulting from the U.K. corporate tax rate change and an increase in valuation allowances during the period.accruals. For the ~~nine~~three months ended ~~October~~April 1, ~~2021,~~2022, the windfall tax benefits upon vesting of certain share-based compensation awards had a benefit of ~~14.5~~3% on the Company’s effective tax rate.

~~14.~~13. Restructuring, Acquisition, and Related Costs

The following table summarizes restructuring, acquisition, and related costs in the accompanying consolidated statements of operations (in thousands):


	Three Months Ended					Nine Months Ended					Three Months Ended
	September 30,			October 1,		September 30,			October 1,		March 31,		April 1,
	2022			2021		2022			2021		2023		2022
2022 restructuring	$	889		$	—	$	889		$	—	$	2,197	$	—
2020 restructuring		887			5,185		2,119			7,688		274		622
2019 restructuring		—			—		—			208
Total restructuring charges	$	1,776		$	5,185	$	3,008		$	7,896		2,471		622
Acquisition and related charges		(151	)		2,935		(358	)		8,589		5		(2,252	)
Total restructuring, acquisition, and related costs	$	1,625		$	8,120	$	2,650		$	16,485	$	2,476	$	(1,630	)

2022 Restructuring

As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2022 restructuring program in the third quarter of 2022. This program is focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program is focused on cost reduction actions that improve gross margins for the overall company in line with the Company's multi-year gross margin expansion program. During the three months ended ~~September 30, 2022,~~March 31, 2023, the Company recorded $~~0.9~~2.2 million in severance ~~costs~~and other charges in connection with the 2022 restructuring program. ~~The $0.9~~ ~~million severance costs were included in the Company's Photonics segment.~~ As of ~~September 30, 2022,~~March 31, 2023, the Company had incurred cumulative costs related to this restructuring plan totaling $~~0.9~~3.6 million. The Company anticipates substantially completing the 2022 restructuring program by the end of 2023 and expects to incur additional restructuring charges of $~~5.0~~3.0 million to $~~6.0~~3.5 million related to the 2022 restructuring program.

24The following table summarizes restructuring costs associated with the 2022 restructuring program by reportable segment (in thousands):

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~


	Three Months Ended
	March 31,		April 1,
	2023		2022
Precision Medicine and Manufacturing	$	723	$	—
Medical Solutions		5		—
Robotics and Automation		1,270		—
Unallocated Corporate and Shared Services		199		—
Total	$	2,197	$	—

2020 Restructuring

~~As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the~~The Company initiated the 2020 restructuring program in the third quarter of 2020. This program is focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program is focused on cost reduction actions that improve gross margins for the overall company. During the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, the Company recorded $~~0.9~~0.3 million ~~and $2.1~~ ~~million, respectively,~~ in severance and other costs in connection with the 2020 restructuring program. As of ~~September 30, 2022,~~March 31, 2023, the Company had incurred cumulative costs related to this restructuring plan totaling $~~10.2~~14.2 million. The ~~Company anticipates substantially completing the~~ 2020 restructuring program is expected to be completed in ~~the first quarter of~~ 2023 and ~~expects~~ to incur additional restructuring charges of $~~1.5~~0.5 million to $~~2.0~~1.0 ~~million related to the 2020 restructuring program.~~million.

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2023

(Unaudited)

The following table summarizes restructuring costs associated with the 2020 restructuring program by reportable segment (in thousands):

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

2022

2021

2022

2021

Photonics
$
758

$
2,349

$
1,952

$
2,839

Vision

101

193

207

890

Precision Motion

22

2,643

(46
)

3,959

Unallocated Corporate and Shared Services

6

—

6

—

Total
$
887

$
5,185

$
2,119

$
7,688


	Three Months Ended
	March 31,		April 1,
	2023		2022
Precision Medicine and Manufacturing	$	206	$	693
Medical Solutions		68		41
Robotics and Automation		—		(112	)
Total	$	274	$	622

~~2019 Restructuring~~

During the fourth quarter of 2018, the Company implemented a restructuring plan intended to realign operations, reduce costs, achieve operational efficiencies and focus resources on growth initiatives (the “2019 restructuring plan”). The Company did not incur any costs related to the 2019 restructuring plan during the three and nine months ended September 30, 2022. As of December 31, 2021, the Company incurred cumulative costs related to this restructuring plan totaling $~~9.0~~ ~~million. The 2019 restructuring program was completed in 2021.~~

Rollforward of Accrued Expenses Related to Restructuring

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):


	Total			Employee Related			Facility			Other			Total			Employee Related			Facility Related			Other
Balance at December 31, 2021	$	2,686		$	2,107		$	550		$	29
Balance at December 31, 2022													$	2,410		$	1,902		$	452		$	56
Restructuring charges		3,008			1,303			1,432			273			2,471			2,041			106			324
Cash payments		(2,519	)		(1,527	)		(722	)		(270	)		(1,320	)		(945	)		(98	)		(277	)
Non-cash charges and other adjustments		(1,325	)		(163	)		(1,160	)		(2	)		34			23			11			—
Balance at September 30, 2022	$	1,850		$	1,720		$	100		$	30
Balance at March 31, 2023													$	3,595		$	3,021		$	471		$	103

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~

Acquisition and Related Charges

Acquisition costs in connection with business combinations, including finders’ fees, legal, valuation, and other professional or consulting fees, totaled $~~0.8~~ ~~million and $1.1~~ ~~million for the three and nine months ended September 30, 2022, respectively, and $2.9~~ ~~million and $4.7~~ ~~million for the three and nine months ended October 1, 2021, respectively. The Company incurred~~ ~~zero~~ ~~costs for the three and nine months ended September 30, 2022, and~~less than $0.1 million ~~and $1.9~~ ~~million in legal costs~~ for both the three ~~and nine~~ months ended ~~October~~March 31, 2023 and the three months ended April 1, ~~2021 related to a dispute involving a company that was acquired in 2019.~~2022. During the three ~~and nine~~ months ended ~~September 30,~~April 1, 2022, the Company recognized $(~~1.0) million and $(1.4) million, respectively, of earn-out expenses (income) related to prior-year acquisitions. During the three and nine months ended October 1, 2021, the Company recognized less than $(0.1) million and~~ $~~1.9~~2.3 million ~~respectively,~~reduction in the fair value of ~~earn-out expenses (income) related to~~certain prior-year ~~acquisitions.~~acquisition contingent considerations. The majority of acquisition and related costs for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023 were included in the Company’s ~~Precision Motion, Photonics, and~~ Unallocated Corporate and Shared Services reportable ~~segments.~~segment. The majority of acquisition and related costs for the three ~~and nine~~ months ended ~~October~~April 1, ~~2021~~2022 were included in the Company’s Precision ~~Motion, Vision,~~Medicine and ~~Unallocated Corporate~~Manufacturing and ~~Shared Services~~Robotics and Automation reportable segments.

~~15.~~14. Commitments and Contingencies

Purchase Commitments

There have been no material changes to the Company’s purchase commitments since December 31, ~~2021.~~2022.

Legal Contingencies

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company reviews the status of each significant matter and assesses the potential financial exposure on a quarterly basis. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available as of the date of the consolidated balance sheet. As additional information becomes available, the Company reassesses the potential liability related to any pending claims and litigations and may revise its estimates. When a material loss contingency is considered reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the potential loss or a range of potential losses, if such an estimate can be reasonably made. Legal fees are expensed as incurred. The Company does not believe that the outcome of these claims will have a material adverse effect on its consolidated financial statements but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect on the consolidated financial statements.

2621

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

Guarantees and Indemnifications

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products, and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which they are involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. These indemnification agreements provide, among other things, that the director or officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such director or officer in connection with any proceeding by reason of their relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and exclusions from indemnification, and the minimum levels of directors and officers liability insurance to be maintained by the Company.

~~16.~~15. Segment Information

Reportable Segments

The Company’s Chief Operating Decision Maker (“CODM”) utilizes financial information to make decisions about allocating resources and assessing performance for the entire Company. The Company evaluates the performance of and allocates resources to its segments based on revenue, gross profit and operating profit. The Company’s reportable segments have been identified based on commonality and adjacency of technologies, applications and customers amongst the Company’s individual product lines. The Company determined that disclosing revenue by specific product ~~was~~is impracticable due to the highly customized and extensive portfolio of technologies offered to customers.

Based upon the information provided to the CODM, the Company has determined that it operates in three reportable segments: ~~Photonics, Vision,~~Precision Medicine and ~~Precision Motion.~~Manufacturing, Medical Solutions, and Robotics and Automation. The reportable segments and their principal activities are described below.

~~Photonics~~Precision Medicine and Manufacturing

The ~~Photonics~~Precision Medicine and Manufacturing segment designs, manufactures and markets photonics-based solutions, including laser scanning, laser beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine ~~products, to customers worldwide.~~products. The segment serves highly demanding photonics-based applications for advanced industrial processes, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures, particularly ophthalmology applications. The vast majority of the segment’s product offerings are sold to OEM ~~customers.~~customers worldwide. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

~~Vision~~Medical Solutions

The ~~Vision~~Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators, pumps and related disposables; visualization solutions; wireless technologies, video recorder and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification (“RFID”) technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The vast majority of the segment’s product offerings are sold to OEM ~~customers.~~customers worldwide. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

~~Precision Motion~~Robotics and Automation

The ~~Precision Motion~~Robotics and Automation segment designs, manufactures and markets optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2023

(Unaudited)

bearings, and air bearing ~~spindles to customers worldwide.~~spindles. The vast majority of the segment’s product offerings are sold to OEM ~~customers.~~customers worldwide. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

~~NOVANTA INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~AS OF SEPTEMBER 30, 2022~~

~~(Unaudited)~~

Reportable Segment Financial Information

Revenue, gross profit, gross profit margin, operating income (loss), and depreciation and amortization expenses by reportable segment were as follows (in thousands, except percentage data):

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

Revenue
2022

2021

2022

2021

Photonics
$
70,799

$
55,263

$
203,042

$
176,113

Vision

73,345

65,346

200,911

196,429

Precision Motion

78,814

57,117

238,577

135,291

Total
$
222,958

$
177,726

$
642,530

$
507,833


	Three Months Ended
	March 31,		April 1,
Revenue	2023		2022
Precision Medicine and Manufacturing	$	69,528	$	62,782
Medical Solutions		77,640		62,050
Robotics and Automation		71,958		79,384
Total	$	219,126	$	204,216


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,			October 1,			September 30,			October 1,			March 31,			April 1,
Gross Profit	2022			2021			2022			2021			2023			2022
Photonics	$	34,699		$	25,311		$	94,268		$	83,014
Vision		28,201			24,763			79,966			76,132
Precision Motion		36,832			27,743			113,846			64,694
Precision Medicine and Manufacturing													$	34,333		$	28,387
Medical Solutions														31,886			25,230
Robotics and Automation														32,815			38,150
Unallocated Corporate and Shared Services		(1,324	)		(1,519	)		(4,151	)		(6,396	)		(1,406	)		(1,491	)
Total	$	98,408		$	76,298		$	283,929		$	217,444		$	97,628		$	90,276

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

Gross Profit Margin
2022

2021

2022

2021

Photonics

49.0
%

45.8
%

46.4
%

47.1
%
Vision

38.4
%

37.9
%

39.8
%

38.8
%
Precision Motion

46.7
%

48.6
%

47.7
%

47.8
%
Total

44.1
%
��

42.9
%

44.2
%

42.8
%


	Three Months Ended
	March 31,			April 1,
Gross Profit Margin	2023			2022
Precision Medicine and Manufacturing		49.4	%		45.2	%
Medical Solutions		41.1	%		40.7	%
Robotics and Automation		45.6	%		48.1	%
Total		44.6	%		44.2	%


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,			October 1,			September 30,			October 1,			March 31,			April 1,
Operating Income (Loss)	2022			2021			2022			2021			2023			2022
Photonics	$	18,351		$	9,294		$	45,782		$	35,885
Vision		8,744			5,606			20,811			12,178
Precision Motion		15,800			14,957			48,222			34,681
Precision Medicine and Manufacturing													$	16,684		$	13,435
Medical Solutions														9,841			5,042
Robotics and Automation														12,000			18,338
Unallocated Corporate and Shared Services		(14,234	)		(14,582	)		(38,580	)		(40,378	)		(12,213	)		(12,532	)
Total	$	28,661		$	15,275		$	76,235		$	42,366		$	26,312		$	24,283


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 30,		October 1,		September 30,		October 1,		March 31,		April 1,
Depreciation and Amortization Expenses	2022		2021		2022		2021		2023		2022
Photonics	$	2,760	$	2,901	$	8,234	$	8,703
Vision		4,240		5,239		12,989		15,793
Precision Motion		6,050		2,691		19,467		5,916
Precision Medicine and Manufacturing									$	2,596	$	2,777
Medical Solutions										3,973		4,427
Robotics and Automation										4,845		6,737
Unallocated Corporate and Shared Services		93		59		309		201		317		103
Total	$	13,143	$	10,890	$	40,999	$	30,613	$	11,731	$	14,044

2823

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

(Unaudited)

Revenue by Geography

The Company aggregates geographic revenue based on the customer locations where products are shipped to. Revenue by geography was as follows (in thousands):


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 30,		October 1,		September 30,		October 1,		March 31,		April 1,
	2022		2021		2022		2021		2023		2022
United States	$	99,230	$	72,972	$	268,585	$	191,699	$	103,842	$	82,715
Germany		34,625		25,313		99,526		71,448		34,862		31,778
Rest of Europe		33,996		34,163		105,327		105,338		29,365		33,373
China		24,209		22,230		80,877		68,286		17,798		26,799
Rest of Asia-Pacific		26,886		21,256		74,400		64,765		28,111		22,840
Other		4,012		1,792		13,815		6,297		5,148		6,711
Total	$	222,958	$	177,726	$	642,530	$	507,833	$	219,126	$	204,216

The majority of revenue from ~~Photonics, Vision~~Precision Medicine and ~~Precision Motion~~Manufacturing, Medical Solutions and Robotics and Automation segments is generated from sales to customers within the United States and Europe. Each segment also generates revenue across the other geographies, with no significant concentration of any segment’s remaining revenue.

Revenue by End Market

The Company primarily operates in two end markets: the medical market and the advanced industrial market. Revenue by end market was approximately as follows:


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,			October 1,			September 30,			October 1,			March 31,			April 1,
	2022			2021			2022			2021			2023			2022
Medical		50	%		53	%		48	%		53	%		54	%		47	%
Advanced Industrial		50	%		47	%		52	%		47	%		46	%		53	%
Total		100	%		100	%		100	%		100	%		100	%		100	%

The majority of revenue from the ~~Photonics~~Precision Medicine and ~~Precision Motion~~Manufacturing and Robotics and Automation segments is generated from sales to customers in the advanced industrial market. The majority of revenue from the ~~Vision~~Medical Solutions segment is generated from sales to customers in the medical market.

2924

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, our ability to manage or mitigate the ~~anticipated impacts~~impact of ~~the COVID-19 pandemic on our business, our financial results~~global supply chain disruptions, inflationary pressures and ~~our financial condition;~~other macroeconomic conditions; our belief that the Purchasing Managers Index (“PMI”) may provide an indication of the impact of general economic conditions on our sales into the advanced industrial end market; our strategy; anticipated financial performance; expected liquidity and capitalization; drivers of revenue growth and our growth expectations in various markets; management’s plans and objectives for future operations, expenditures and product development, and investments in research and development; business prospects; potential of future product releases and expansion of our product and service offerings; anticipated revenue performance; industry trends; market conditions; our competitive positions; changes in economic and political conditions, including supply chain ~~constraints;~~disruptions and constraints and inflationary pressures; changes in accounting principles; changes in actual or assumed tax liabilities; expectations regarding tax exposures; anticipated reinvestment of future earnings and dividend policy; anticipated expenditures in regard to the Company’s benefit plans; future ~~acquisitions;~~acquisitions and integration and anticipated benefits from acquisitions and dispositions; anticipated economic benefits ~~costs~~ and ~~timelines~~expected costs of restructuring programs; ability to repay our indebtedness; our intentions regarding the use of cash; expectations regarding legal and regulatory requirements, including environmental requirements, and our compliance thereto; and other statements that are not historical facts. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with epidemics or pandemics, such as the COVID-19 pandemic, and other events outside of our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our exposure to the credit risk of some of our customers and in weakened markets; ~~our reliance on third party distribution channels; our reliance on original equipment manufacturer customers;~~ being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021~~2022 under the heading “Risk Factors”,as updated in our other filings with the Securities and Exchange Commission. In this Quarterly Report on Form 10-Q, the words “expects,” “intends,” “anticipates,” “estimates,” “believes,” “future,” “plans,” “aims,” “would,” “could,” “should,” “potential,” “continues,” and similar words or expressions (as well as other words or expressions referencing future events, conditions, or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such forward-looking statements to reflect any changes in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.

3025

Accounting Period

The interim consolidated financial statements of Novanta Inc. ~~and its subsidiaries (collectively referred to as the~~(the “Company”, “Novanta”, “we”, “us”, “our”) are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, except for the fourth quarter which always ends on December 31.

Business Overview

We are a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in ~~photonics, vision~~precision medicine and ~~precision motion~~manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables us to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.

During the first quarter of 2023, we changed the names of our reportable segments from “Photonics” to “Precision Medicine and Manufacturing”, from “Vision” to “Medical Solutions”, and from “Precision Motion” to “Robotics and Automation”, respectively. The segment name changes did not result in any change to the compositions of our segments and therefore did not result in any change to historical results.

Reportable Segments

We operate in three reportable segments: ~~Photonics, Vision,~~Precision Medicine and ~~Precision Motion.~~Manufacturing, Medical Solutions, and Robotics and Automation. The reportable segments and their principal activities are summarized below.

~~Photonics~~Precision Medicine and Manufacturing

Our ~~Photonics~~Precision Medicine and Manufacturing segment designs, manufactures and markets photonics-based solutions, including laser scanning, laser beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products to customers worldwide. The segment serves highly demanding photonics-based applications for advanced industrial processes, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures, particularly ophthalmology applications. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

~~Vision~~Medical Solutions

Our ~~Vision~~Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators, pumps and related disposables; visualization solutions; wireless technologies, video recorder and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification (“RFID”) technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

~~Precision Motion~~Robotics and Automation

Our ~~Precision Motion~~Robotics and Automation segment designs, manufactures and markets optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

End Markets

We primarily operate in two end markets: the medical market and the advanced industrial market.

Medical Market

For the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the medical market accounted for approximately ~~48%~~54% of our revenue. Revenue from our products sold to the medical market is generally affected by hospital and other healthcare provider capital spending, growth rates of surgical procedures, changes in regulatory requirements and laws, aggregation of purchasing by healthcare networks, changes

in technology requirements, timing of OEM customers’ product development and new product launches, changes in customer or patient preferences, and general demographic trends.

Advanced Industrial Market

For the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the advanced industrial market accounted for approximately ~~52%~~46% of our revenue. Revenue from our products sold to the advanced industrial market is affected by several factors, including changing technology requirements and preferences of our customers, productivity or quality investments in a manufacturing environment, financial conditions of our customers, changes in regulatory requirements and laws, and general economic conditions. We believe that the ~~Purchasing Managers Index (PMI)~~PMI on manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on our sales into the advanced industrial market.

Strategy

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including:

•

disciplined focus on our diversified business model of providing ~~components and sub-systems~~functionality to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets;

•

improving our business mix to increase medical sales as a percentage of total revenue by:

introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment;

deepening our key account management relationships with and driving cross selling of our product offerings to leading medical equipment manufacturers; and

pursuing complementary medical technology acquisitions;

•

increasing our penetration of high growth advanced industrial applications, such as laser materials processing, intelligent end-of-arm robotic technology solutions, robotics, laser additive manufacturing, automation and metrology, by working closely with OEM customers to launch application specific products that closely match the requirements of each application;

•

broadening our portfolio of enabling proprietary technologies and capabilities through increased investment in new product development, and investments in application development to further penetrate existing customers, while expanding the applicability of our solutions to new markets;

•

broadening our product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications;

•

expanding sales and marketing channels to reach new target customers;

•

improving our existing operations to expand profit margins and improve customer satisfaction by implementing lean manufacturing principles, strategic sourcing across our major production sites; and optimizing and limiting the growth of our fixed cost base; and

•

attracting, retaining, and developing world-class talented, diverse, and motivated employees.

Significant Events and Updates

~~Acquisition of MPH Medical Devices S.R.O.~~Business Environment

On August 11, 2022, we acquired 100% of the outstanding shares of MPH Medical Devices S.R.O. ("MPH"), a Czech Republic-based manufacturer of medical consumables with plastics specialization in making disposable tub-set-like products, for a total purchase price of €21.8 million ($22.4 million), net of cash acquired. The acquisition was financed with borrowings under our revolving credit facility and cash available on hand. The addition of MPH is expected to expand the Company's manufacturing capacity and capabilities in the medical disposable tube set products within the Vision reportable segment.

~~Amendment to Credit Agreement~~

On March 10, 2022, we entered into an amendment (the “Fifth Amendment”) to the Third Amended and Restated Credit Agreement, dated as of December 31, 2019 (as amended, the “Credit Agreement”). The Fifth Amendment amends the Credit Agreement to extend the maturity date thereof from December 31, 2024 to March 10, 2027, update the pricing grid, replace LIBOR with SOFR as the reference rate for U.S. dollar borrowings, and increase the uncommitted accordion option from $200 million to $350 million.

~~Impact of COVID-19 and~~Global Supply Chain Disruptions ~~on Our Business~~

In response to the COVID-19 pandemic, we have taken proactive, aggressive actions to protect the health and safety of our employees. We established steering committees at both the corporate level and at each of our major facilities to provide leadership for and manage our COVID-19 risk mitigation actions and countermeasures. We established rigorous safety measures in all of our facilities and have adapted our COVID-19 safety measures as the pandemic and related government mandates evolved overOver the past ~~two years. We expect to continue some of these measures until~~three years, we determine that the COVID-19 pandemic is adequately contained for purposes of our business. In connection with our COVID-19 remediation actions, we have incurred additional costs to protect the health of our employees, including investments in technologies and monitoring equipment, weekly testing of unvaccinated employees for COVID-19 at certain locations and rearranging some of our facilities to accommodate social distancing and flexible post-pandemic work environment.

Infection rates and the corresponding public health restrictions varied across the countries in which we operate. Some governmental authorities have continued to implement numerous evolving measures to try to contain the virus, such as travel bans and restrictions, masking recommendations and mandates, vaccine recommendations and mandates, limitations on gatherings, mandatory quarantines, shelter-in-place orders, and business shutdowns. While COVID-19 restrictions have been relaxed in the U.S. and Europe, in response to outbreaks of infection in various locations within China, governmental authorities have implemented lockdown orders in some areas, significantly slowing economic and business activities. Our manufacturing and distribution operations in China have been impacted to a limited degree by these lockdowns. The extent to which government lockdowns in China or any other country will impact our business and our financial results will depend on future developments, which are highly uncertain and cannot be reasonably estimated at this time.

~~Through September 30, 2022, we have~~ experienced disruptions to our supply chain as a result of the COVID-19 pandemic and global electronics and other raw material shortages. While we regularly monitor the manufacturing output of companies in our supply chain, disruptions to our suppliers and/or sub-suppliers ~~caused by these events~~ could further challenge our ability ~~to obtain raw materials or components required~~ to manufacture our products, adversely affecting our operations and customer relationships.

To mitigate the risk of supply chain interruptions, ~~from the COVID-19 pandemic and the global electronics and other raw material shortages,~~ we are identifying alternative suppliers and distributors, sourcing raw materials from different supplier and distributor locations, modifying our product designs ~~where feasible~~ to allow for alternative components to be used without compromising quality and performance, ~~or other requirements,~~ in-sourcing production of parts where feasible, and taking other actions to ensure a sustainable supply of raw materials. Despite our mitigation actions, if certain suppliers cannot produce a key part or component for us, or if the receipt of certain materials is otherwise delayed, we may miss our scheduled shipment deadlines and our relationship with customers may be harmed.

Additionally, restrictions on or disruptions of transportation, such as reduced availability of air transports, port closures and backlogs and increased border controls or closures, have resulted in higher costs and delays ~~both~~ for obtaining raw materials from ~~suppliers~~suppliers. Our supply chain disruptions and ~~for shipping finished products~~customer orders to ~~customers.~~secure supply caused

significantly elevated customer order backlog levels in the last two years. As of March 31, 2023, our backlog was almost double our average pre-COVID pandemic backlog levels due to longer customer lead times. We anticipate that our customers will gradually shorten their order lead times as supply chain disruptions ease over time in the near future.

Inflationary Pressures

The COVID-19 pandemic and the global ~~electronics and other raw material shortages~~supply chain disruptions have caused inflationary pressures on the market prices for ~~certain of our parts and primary~~ raw materials and components as well as increases in the costs of labor. We continue to experience higher than normal inflation of raw materials and components prices as well as labor ~~freight, packaging, energy and other consumables that are used in our manufacturing processes.~~costs. We have generally been able to offset increases in these costs through various productivity ~~and~~ cost reduction initiatives, as well as ~~adjusting~~increasing our selling prices to pass through some of these higher costs to our ~~customers; however,~~customers. However, our ability to raise our selling prices depends on market conditions and competitive dynamics. Given the timing of our actions compared to the timing of these inflationary pressures, there may be periods during which we are unable to fully recover the increases in our costs. Additionally, the inflationary pressures have given rise to significant increases in interest rates as various governments used monetary policy to reduce inflation. As a result, our weighted average interest rate increased from approximately 2.5% as of April 1, 2022 to approximately 5.6% as of March 31, 2023.

Russia Ukraine Conflict

In February 2022, Russian forces invaded Ukraine. In response, the ~~United States,~~U.S., the European Union (“EU”), and several other countries imposed economic and trade sanctions and other restrictions (collectively, “global sanctions”) targeting Russia and Belarus. Russia then imposed retaliatory economic measures against the ~~United States,~~U.S., the ~~European Union,~~EU, and several other countries.

Our sales to Russia ~~are~~have not been material. We ~~continue to assess~~also do not have any assets, employees or third-party contractors in Russia or Ukraine. The duration of the conflict and ~~related global~~further sanctions ~~and take steps to attempt to mitigate the potential negative~~could have further impact on ~~our business. Any longer-term impact to our business is currently unknown due~~the global economy and inflation. Due to the uncertainty around the duration of the conflict, ~~any further global sanctions and their broader impact on the global economy and inflation.~~these longer-term factors are unknown to our business.

Results of Operations for the Three ~~and Nine~~ Months Ended ~~September 30, 2022~~March 31, 2023 Compared with the Three ~~and Nine~~ Months Ended ~~October~~April 1, ~~2021~~2022

Overview of Financial Results

Total revenue of ~~$223.0~~$219.1 million for the three months ended ~~September 30, 2022~~March 31, 2023 increased ~~$45.2~~$14.9 million, or ~~25.5%~~7.3%, from the prior year period primarily due to ~~revenue from prior year acquisitions and~~ increased demand in the advanced industrial and medical ~~markets.~~markets and revenue from a prior year acquisition. The effect of our prior year ~~acquisitions~~acquisition resulted in an increase in revenue of ~~$22.3~~$3.5 million, or ~~12.6%~~1.7%. In addition, foreign currency exchange rates adversely impacted our revenue by ~~$13.7~~$5.8 million, or ~~7.7%~~2.8%, for the three months ended ~~September 30, 2022.~~

Total revenue of $642.5 million for the nine months ended September 30, 2022 increased $134.7 million, or 26.5%, from the prior year period primarily due to revenue from prior year acquisitions and increased demand in the advanced industrial and medical markets. The effect of our prior year acquisitions resulted in an increase in revenue of $90.1 million, or 17.7%. In addition, foreign currency exchange rates adversely impacted our revenue by $25.6 million, or 5.0%, for the nine months ended September 30, 2022.March 31, 2023.

Operating income of ~~$28.7~~$26.3 million for the three months ended ~~September 30, 2022~~March 31, 2023 increased ~~$13.4~~$2.0 million, or ~~87.6%~~8.4%, from the prior year period. This increase was attributable to an increase in gross profit of ~~$22.1~~$7.4 million primarily attributable to higher revenue, an increase in gross profit margin, and a decrease in amortization expense of $2.3 million, partially offset by an increase in restructuring, acquisition, and related charges of ~~$6.5~~$4.1 million, ~~partially offset by~~ an increase in research and development and engineering ~~(“R&D”)~~ expenses of ~~$3.9~~$1.9 million, and an increase in selling, general and administrative ~~(“SG&A”)~~ expenses of ~~$9.0 million and an increase in amortization expense of $2.3 million.~~

Operating income of $76.2 million for the nine months ended September 30, 2022 increased $33.9 million, or 79.9%, from the prior year period. This increase was attributable to an increase in gross profit of $66.5 million primarily attributable to higher revenue, an increase in gross profit margin, and a decrease in restructuring, acquisition, and related charges of $13.8 million, partially offset by an increase in R&D expenses of $10.8 million, an increase in SG&A expenses of $26.0 million and an increase in amortization expense of $9.7$1.6 million.

Basic earnings per common share (“Basic EPS”) of ~~$0.63~~$0.51 for the three months ended ~~September 30, 2022 increased $0.25~~March 31, 2023 decreased $0.02 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of ~~$0.63~~$0.51 for the three months ended ~~September 30, 2022 increased $0.25~~March 31, 2023 decreased $0.02 from the prior year period. The ~~increases~~decreases were primarily attributable to an increase in ~~operating income,~~interest expense, partially offset by an increase in ~~income tax provision.~~operating income.

Basic EPS of $1.65 for the nine months ended September 30, 2022 increased $0.62 from the prior year period. Diluted EPS of $1.64 for the nine months ended September 30, 2022 increased $0.62 from the prior year period. The increases were primarily attributable to an increase in operating income, partially offset by an increase in income tax provision.

Revenue

The following table sets forth external revenue by reportable segment for the periods noted (dollars in thousands):

Three Months Ended

September 30,

October 1,

Increase

Percentage

2022

2021

(Decrease)

Change

Photonics
$
70,799

$
55,263

$
15,536

28.1
%
Vision

73,345

65,346

7,999

12.2
%
Precision Motion

78,814

57,117

21,697

38.0
%
Total
$
222,958

$
177,726

$
45,232

25.5
%


	Three Months Ended
	March 31,		April 1,		Increase			Percentage
	2023		2022		(Decrease)			Change
Precision Medicine and Manufacturing	$	69,528	$	62,782	$	6,746			10.7	%
Medical Solutions		77,640		62,050		15,590			25.1	%
Robotics and Automation		71,958		79,384		(7,426	)		(9.4	)%
Total	$	219,126	$	204,216	$	14,910			7.3	%

Nine Months Ended

September 30,

October 1,

Increase

Percentage

2022

2021

(Decrease)

Change

Photonics
$
203,042

$
176,113

$
26,929

15.3
%
Vision

200,911

196,429

4,482

2.3
%
Precision Motion

238,577

135,291

103,286

76.3
%
Total
$
642,530

$
507,833

$
134,697

26.5
%

3428

~~Photonics~~

~~Photonics~~Precision Medicine and Manufacturing

Precision Medicine and Manufacturing segment revenue for the three months ended ~~September 30, 2022~~March 31, 2023 increased by ~~$15.5~~$6.7 million, or ~~28.1%~~10.7%, versus the prior year period, primarily due to increased demand in advanced industrial and medical markets.

~~Photonics segment revenue for the nine months ended September 30, 2022increased by $26.9 million, or 15.3%, versus the prior year period, primarily due to increased demand in advanced industrial and medical markets.~~Medical Solutions

~~Vision~~

~~Vision~~Medical Solutions segment revenue for the three months ended ~~September 30, 2022~~March 31, 2023 increased by ~~$8.0~~$15.6 million, or ~~12.2%, versus the prior year period, primarily due to increases in sales from our minimally invasive surgery products.~~

~~Vision segment revenue for the nine months ended September 30, 2022 increased by $4.5 million, or 2.3%~~25.1%, versus the prior year period, primarily due to increases in sales from our minimally invasive surgery products ~~partially offset by shortages~~and detection and analysis products, and $3.5 million of ~~raw materials and other supply chain disruptions.~~revenue contributions from our 2022 acquisition.

~~Precision Motion~~Robotics and Automation

~~Precision Motion~~Robotics and Automation segment revenue for the three months ended ~~September 30, 2022~~March 31, 2023 ~~increased~~decreased by ~~$21.7~~$7.4 million, or ~~38.0%~~9.4%, versus the prior year period, primarily due to ~~$20.3 million of revenue contributions from 2021 acquisitions.~~

~~Precision Motion segment revenue for the nine months ended September 30, 2022increased by $103.3 million, or 76.3%, versus the prior yearperiod, primarily due to $88.0 million of revenue contributions from 2021 acquisitions and increased~~a decrease in demand in ~~advanced industrial and medical markets.~~the microelectronics market.

Gross Profit and Gross Profit Margin

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

2022

2021

2022

2021

Gross profit:

Photonics
$
34,699

$
25,311

$
94,268

$
83,014

Vision

28,201

24,763

79,966

76,132

Precision Motion

36,832

27,743

113,846

64,694

Unallocated Corporate and Shared Services

(1,324
)

(1,519
)

(4,151
)

(6,396
)
Total
$
98,408

$
76,298

$
283,929

$
217,444

Gross profit margin:

Photonics

49.0
%

45.8
%

46.4
%

47.1
%
Vision

38.4
%

37.9
%

39.8
%

38.8
%
Precision Motion

46.7
%

48.6
%

47.7
%

47.8
%

Total

44.1
%

42.9
%

44.2
%

42.8
%


	Three Months Ended
	March 31,			April 1,
	2023			2022
Gross profit:
Precision Medicine and Manufacturing	$	34,333		$	28,387
Medical Solutions		31,886			25,230
Robotics and Automation		32,815			38,150
Unallocated Corporate and Shared Services		(1,406	)		(1,491	)
Total	$	97,628		$	90,276
Gross profit margin:
Precision Medicine and Manufacturing		49.4	%		45.2	%
Medical Solutions		41.1	%		40.7	%
Robotics and Automation		45.6	%		48.1	%
Total		44.6	%		44.2	%

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, trade tariffs, freight costs, headcount, inventory obsolescence and warranty expenses.

~~Photonics~~Precision Medicine and Manufacturing

~~Photonics~~Precision Medicine and Manufacturing segment gross profit for the three months ended ~~September 30, 2022~~March 31, 2023 increased ~~$9.4~~$5.9 million, or ~~37.1%~~20.9%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. ~~Photonics~~Precision Medicine and Manufacturing segment gross profit margin was ~~49.0%~~49.4% for the three months ended ~~September 30, 2022,~~March 31, 2023, versus a gross profit margin of ~~45.8%~~45.2% for the prior year period. The increase in gross profit margin was primarily attributable to improved factory productivity and ~~utilization.~~favorable product mix.

Medical Solutions

~~Photonics segment gross profit for the nine months ended September 30, 2022increased $11.3 million, or 13.6%, versus the prior year period, primarily due to an increase in revenue. Photonics segment gross profit margin was 46.4% for the nine months~~

ended September 30, 2022, versus a gross profit margin of 47.1% for the prior year period. The decrease in gross profit margin was primarily attributable to supply chain disruptions and overall raw material cost inflation.

~~Vision~~

~~Vision~~Medical Solutions segment gross profit for the three months ended ~~September 30, 2022~~March 31, 2023 increased ~~$3.4~~$6.7 million, or 13.9%, versus the prior year period, primarily due to an increase in revenue. Vision segment gross profit margin was 38.4% for the three months ended September 30, 2022, versus a gross profit margin of 37.9% for the prior year period.

~~Vision segment gross profit for the nine months ended September 30, 2022increased $3.8 million, or 5.0%~~26.4%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. ~~Vision~~Medical Solutions segment gross profit margin was ~~39.8%~~41.1% for the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, versus a gross profit margin of ~~38.8%~~40.7% for the prior year period. ~~The increase in gross profit margin was primarily attributable to improved factory efficiency.~~

~~Precision Motion~~

~~Precision Motion~~Robotics and Automation

Robotics and Automation segment gross profit for the three months ended ~~September 30, 2022~~March 31, 2023 ~~increased $9.1~~decreased $5.3 million, or ~~32.8%~~14.0%, versus the prior year period, primarily due to ~~an increase~~a decrease in ~~revenue. Precision Motion~~ both revenue and gross profit margin. Robotics and Automationsegment gross profit margin was ~~46.7%~~45.6% for the three months ended ~~September 30, 2022,~~March 31, 2023, versus a gross profit margin of ~~48.6%~~48.1% for the prior year

period. The decrease in gross profit margin was primarily attributable to ~~supply chain disruptions, raw material cost inflation and unfavorable product mix.~~

~~Precision Motion segment gross profit for the nine months ended September 30, 2022increased $49.2 million, or 76.0%, versus the prior year period, primarily~~inefficient factory utilization due to ~~an increase~~a decrease in ~~revenue. Precision Motion segment gross profit margin was 47.7% for~~demand in the ~~nine months ended September 30, 2022, versus a gross profit margin of 47.8% for the prior year period.~~microelectronics market.

Unallocated Corporate and Shared Services

Unallocated corporate and shared services costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments. These costs for the three months ended ~~September 30, 2022~~March 31, 2023 decreased by ~~$0.2~~$0.1 million versus the prior year period.

~~Unallocated corporate and shared services costs for the nine months ended September 30, 2022decreased by $2.2 million versus the prior year period primarily due to reduced COVID-19 testing costs for employees of $3.1 million.~~

Operating Expenses

The following table sets forth operating expenses for the periods noted (in thousands):


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 30,		October 1,		September 30,		October 1,		March 31,		April 1,
	2022		2021		2022		2021		2023		2022
Research and development and engineering	$	21,349	$	17,468	$	63,866	$	53,104	$	22,828	$	20,929
Selling, general and administrative		40,301		31,296		120,191		94,189		40,923		39,352
Amortization of purchased intangible assets		6,472		4,139		20,987		11,300		5,089		7,342
Restructuring, acquisition, and related costs		1,625		8,120		2,650		16,485		2,476		(1,630	)
Total	$	69,747	$	61,023	$	207,694	$	175,078	$	71,316	$	65,993

Research and Development and Engineering Expenses

Research and Development and Engineering (“R&D”) expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were ~~$21.3~~$22.8 million, or ~~9.6%~~10.4% of revenue, during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$17.5~~$20.9 million, or ~~9.8%~~10.2% of revenue, during the prior year period. R&D expenses increased in terms of total dollars and as a percentage of revenue, primarily due to higher compensation related expenses ~~related to 2021 acquisitions.~~

~~R&D expenses were $63.9 million, or 9.9%~~as a result of revenue, during the nine months ended September 30, 2022, versus $53.1 million, or 10.5% of revenue, during the prior year period. R&D expenses increased in terms of total dollars primarily due to expenses related to 2021 acquisitions.higher headcount.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were ~~$40.3~~$40.9 million, or ~~18.1%~~18.7% of revenue, during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$31.3~~$39.4 million, or ~~17.6%~~19.3% of revenue, during the prior year period. SG&A expenses increased in terms of total dollars ~~and as a percentage of revenue~~ primarily due to ~~SG&A expenses related to 2021 acquisitions and~~ increases in ~~variable~~ compensation ~~and discretionary spending.~~

~~SG&A~~related expenses were $120.2 million, or 18.7% of revenue, during the nine months ended September 30, 2022, versus $94.2 million, or 18.5% of revenue, during the prior year period. SG&A expenses increased in terms of total dollars and as a percentage of revenue primarily due to SG&A expenses related to 2021 acquisitions and increases in variable compensation and discretionary spending.

Amortization of Purchased Intangible Assets

Amortization of purchased intangible assets, excluding amortization of developed technologies that is included in cost of revenue, was ~~$6.5~~$5.1 million, or ~~2.9%~~2.3% of revenue, during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$4.1~~$7.3 million, or ~~2.3%~~3.6% of revenue, during the prior year period. The ~~increase,~~decrease, in terms of total dollars and as a percentage of revenue, was ~~the result of more acquired intangible assets from 2021 acquisitions.~~

~~Amortization of purchased intangible assets, excluding amortization of developed technologies that is included~~primarily due to certain intangibles being fully amortized in cost of revenue, was $21.0 million, or 3.3% of revenue, during the nine months ended September 30, 2022, versus $11.3 million, or 2.2% of revenue, during the prior year period. The increase, in terms of total dollars and as a percentage of revenue, was the result of more acquired intangible assets from 2021 acquisitions.2022.

Restructuring, Acquisition, and Related Costs

We recorded restructuring, acquisition, and related costs of ~~$1.6~~$2.5 million during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$8.1~~$(1.6) million during the prior year period. During the three months ended April 1, 2022, the Company recognized $2.3 million reduction in the fair value of certain prior-year acquisition contingent consideration. The ~~acquisition and related~~restructuring costs ~~decreased~~during the three months ended March 31, 2023 increased $1.8 million primarily due to a $2.1 million reduction in acquisition and related expenses and a $1.0 million reduction in earnout expense related to a prior year acquisition. The restructuring costs decreased $3.5 million primarily related to decreased expenses for the restructuring plans.

We recorded restructuring, acquisition, and related costs of $2.7 million during the nine months ended September 30, 2022, versus $16.5 million during the prior year period. The acquisition and related costs decreased primarily due to a $3.4 million reduction in earnoutincreased expenses related to ~~prior year acquisitions, a $2.0 million reduction in legal fees and a $3.6 million reduction in other acquisition and related expenses. The~~the 2022 restructuring ~~costs decreased $4.9 million related to decreased expenses for the restructuring plans.~~plan.

Operating Income (Loss) by Segment

The following table sets forth operating income (loss) by segment for the periods noted (in thousands):


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,			October 1,			September 30,			October 1,			March 31,			April 1,
	2022			2021			2022			2021			2023			2022
Operating Income (Loss)
Photonics	$	18,351		$	9,294		$	45,782		$	35,885
Vision		8,744			5,606			20,811			12,178
Precision Motion		15,800			14,957			48,222			34,681
Precision Medicine and Manufacturing													$	16,684		$	13,435
Medical Solutions														9,841			5,042
Robotics and Automation														12,000			18,338
Unallocated Corporate and Shared Services		(14,234	)		(14,582	)		(38,580	)		(40,378	)		(12,213	)		(12,532	)
Total	$	28,661		$	15,275		$	76,235		$	42,366		$	26,312		$	24,283

~~Photonics~~Precision Medicine and Manufacturing

~~Photonics~~Precision Medicine and Manufacturing segment operating income was ~~$18.4~~$16.7 million, or ~~25.9%~~24.0% of revenue, during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$9.3~~$13.4 million, or ~~16.8%~~21.4% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of ~~$9.4~~$5.9 million, ~~and a decrease~~partially offset by an increase in restructuring, acquisition, and related costs of ~~$1.6 million, partially offset by an increase in R&D costs of $1.0~~$2.0 million, and an increase in ~~SG&A~~R&D expenses of $0.9 million.

37Medical Solutions

~~Photonics~~Medical Solutions segment operating income was ~~$45.8~~$9.8 million, or ~~22.5%~~12.7% of revenue, during the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$35.9~~$5.0 million, or ~~20.4%~~8.1% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of ~~$11.3 million, and a decrease in restructuring, acquisition, and related costs of $2.6~~$6.7 million, partially offset by an increase in R&D ~~costs~~expenses of ~~$2.0~~$1.3 million and an increase in ~~SG$A~~SG&A expenses of ~~$1.8~~$0.9 million.

~~Vision~~Robotics and Automation

~~Vision~~Robotics and Automation segment operating income was ~~$8.7~~$12.0 million, or ~~11.9%~~16.7% of revenue, during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$5.6~~$18.3 million, or ~~8.6%~~23.1% of revenue, during the prior year period. The ~~increase~~decrease in operating income was primarily due to ~~an increase~~a decrease in gross profit of ~~$3.4~~$5.3 million, ~~and a decrease~~an increase in restructuring, acquisition, and related costs of ~~$0.3~~$1.9 million, ~~partially offset by~~and an increase in SG&A expenses of ~~$0.8 million.~~

~~Vision segment operating income was $20.8~~$1.0 million, or 10.4% of revenue, during the nine months ended September 30, 2022, versus $12.2 million, or 6.2% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of $3.8 million, a decrease in restructuring, acquisition, and related costs of $3.2 million, a decrease in R&D costs of $1.2 million, andpartially offset by a decrease in amortization expense of ~~$1.2~~$1.8 million ~~partially offset by an increase in SG&A expenses of $0.8 million.~~

~~Precision Motion~~

Precision Motion segment operating income was $15.8 million, or 20.0% of revenue, during the three months ended September 30, 2022, versus $15.0 million, or 26.2% of revenue, during the prior year period. The increase in operating income was primarily due to ~~an increase~~certain intangible assets being fully amortized in gross profit of $9.1 million and a decrease in restructuring, acquisition, and related costs of $2.6 million, partially offset by increases in R&D costs of $2.7 million, SG&A expenses of $5.4 million, and amortization expense of $2.8 million primarily as a result of prior year acquisitions.

Precision Motion segment operating income was $48.2 million, or 20.2% of revenue, during the nine months ended September 30, 2022, versus $34.7 million, or 25.6% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of $49.2 million, and a decrease in restructuring, acquisition, and related costs of $4.2 million, partially offset by increases in R&D costs of $10.0 million, SG&A expenses of $19.1 million, and amortization expense of $10.8 million primarily as a result of prior year acquisitions.2022.

Unallocated Corporate and Shared Services

Unallocated corporate and shared services costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments, including certain restructuring and most acquisition costs. These costs for the three months ended ~~September 30, 2022~~March 31, 2023 decreased by $0.3 million versus the prior year period primarily due to a decrease in costs related to COVID-19 testing for employees of $0.4 million included in cost of revenue, and a decrease in restructuring, acquisition, and related costs of $2.1 million, partially offset by an increase in SG&A expenses of $1.9 million.

~~Unallocated corporate and shared services costs for the nine months ended September 30, 2022~~decreased by $1.8 million versus the prior year period primarily due to a decrease in costs related to COVID-19 testing for employees of $3.1 million included in cost of revenue, and a decrease in restructuring, acquisition, and related costs of $3.8 million, partially offset by an increase in SG&A expenses of $4.3 million.period.

Other Income and Expense Items

The following table sets forth other income and expense items for the periods noted (in thousands):

Three Months Ended

Nine Months Ended

September 30,

October 1,

September 30,

October 1,

2022

2021

2022

2021

Interest income (expense), net
$
(4,062
)

$
(1,710
)

$
(9,928
)

$
(4,496
)
Foreign exchange transaction gains (losses), net

2,086

34

2,307

(299
)
Other income (expense), net

87

(71
)

(390
)

(238
)


	Three Months Ended
	March 31,			April 1,
	2023			2022
Interest income (expense), net	$	(6,332	)	$	(3,109	)
Foreign exchange transaction gains (losses), net	$	(77	)	$	69
Other income (expense), net	$	(166	)	$	(545	)

Interest Income (Expense), Net

Net interest expense was ~~$4.1~~$6.3 million for the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$1.7~~$3.1 million in the prior year period. The increase in net interest expense was primarily due to ~~an increase in average debt levels and~~ an increase in the weighted average interest rate on our senior credit facilities. The weighted average interest rate on our senior credit facilities was ~~3.37%~~5.55% during the three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~2.28%~~2.49% during the prior year period.

Net interest expense was $9.9 million for the nine months ended September 30, 2022, versus $4.5 million in the prior year period. The increase in net interest expense was primarily due to an increase in average debt levels and an increase in the weighted average interest rate on our senior credit facilities. The weighted average interest rate on our senior credit facilities was 2.72% during the nine months ended September 30, 2022, versus 2.12% during the prior year period.31

Foreign Exchange Transaction Gains (Losses), Net

Foreign exchange transaction gains (losses) were ~~$2.1 million net gains~~nominal for both the three months ended ~~September 30, 2022, versus less than $0.1 million net gains in~~March 31, 2023 and the ~~prior year period. The increase in net gains was primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro.~~

~~Foreign exchange transaction gains (losses) were $2.3 million net gains for the nine~~three months ended September 30, 2022, versus $(0.3) million net losses in the prior year period. The increase in net gains was primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro.April 1, 2022.

Other Income (Expense), Net

Net other expense was nominal for both the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023 and ~~October~~the three months ended April 1, ~~2021, respectively.~~2022.

Income Tax Provision (Benefit)

Our effective tax rate for the three months ended ~~September 30, 2022~~March 31, 2023 was ~~16.0%~~7.5%, versus ~~(0.6)%~~9.1% for the prior year period. Our effective tax rate of ~~16.0%~~7.5% for the three months ended September 30, 2022 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, and R&D tax credits, partially offset by disallowed compensation expenses and uncertain tax position accruals.

Our effective tax rate of (0.6%) for the three months ended October 1, 2021 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, other tax credits, windfall tax benefits upon vesting of certain share-based compensation awards and a release of uncertain tax position reserves due to expiration of statutes of limitation, partially offset by an increase in our valuation allowance.

~~Our effective tax rate for the nine months ended September 30, 2022 was 13.8%, versus 2.0% for the prior year period. Our effective tax rate of 13.8% for the nine months ended September 30, 2022~~March 31, 2023 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, R&D tax credits and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by disallowed compensation ~~expenses~~ and uncertain tax position accruals. For the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the windfall tax benefits upon vesting of certain stock-based compensation awards had a benefit of ~~0.2%~~8.2% on our effective tax rate.

Our effective tax rate of ~~2.0%~~9.1% for the ~~nine~~three months ended ~~October~~April 1, ~~2021~~2022 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for Foreign Derived Intangible Income, U.K. patent box deductions, other tax credits ~~a release of uncertain tax positions reserves,~~ and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by ~~the revaluation of long term deferred~~disallowed compensation and uncertain tax ~~balances resulting from the U.K. corporate tax rate change during the period and an increase in our valuation allowances.~~position accruals. For the ~~nine~~three months ended ~~October~~April 1, ~~2021,~~2022, the windfall tax benefits upon vesting of certain ~~share-based~~stock-based compensation awards had a benefit of ~~14.5%~~3% on our effective tax rate.

~~The Inflation Reduction Act~~On December 12, 2022, the EU member states agreed to implement the Organization for Economic Co-operation and Development’s (“OECD”) Pillar Two Model Rules to be effective as of ~~2022 (the "IRA") was passed into law on August 16, 2022. The provisions~~January 2024. These rules will impose a global corporate minimum income tax rate of 15%. Other countries are also actively considering changes to their tax laws to adopt certain parts of the ~~IRA~~OECD’s proposals. The OECD continues to release additional guidance on these rules. The Company is analyzing the potential impact and will be effective beginning with fiscal year 2023, with certain exceptions. The IRA has several new provisions including a 15% corporate alternative minimum tax ("CAMT") for certain large corporations that have at least an average of $1.0 billion of adjusted financial statement income over a consecutive three-tax-year period. The IRA also introduced a 1% excise tax imposed on certain stock

repurchases by publicly traded U.S. corporations made after December 31, 2022. Based on our initial evaluation, we do not believe the IRA will have a material impact on our income tax provision and cash taxes. We continue to monitor the ~~changes in tax laws and regulations to evaluate their potential impact on our business.~~related developments.

Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest payments. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowing capacity under our revolving credit facility provides another potential source of liquidity for any future capital expenditures and other liquidity needs. In addition, we have the ability to expand our borrowing capacity by up to $350.0 million by exercising the accordion option under our revolving credit agreement. We may also seek to raise additional capital, which could be in the form of bonds, convertible debt or preferred or common equity, to fund business development activities or other future investing cash requirements, subject to approval by the lenders in the Third Amended and Restated Credit Agreement (as amended, the “Credit Agreement”). There is no assurance that such capital will be available on reasonable terms or at all.

Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, risks associated with events outside of our control, such as economic consequences of global pandemics and geo-political conflicts, monetary policy changes in the ~~COVID-19 pandemic~~U.S. and other countries and their impact on the ~~Russia-Ukraine war, worsening~~global financial markets, supply chain disruptions and electronics and other material shortages, a decrease in demand for our products, our ability to integrate current and future acquisitions, deterioration in certain financial ratios, ~~higher interest rates in the U.S. and Europe,~~ availability of borrowings under our revolving credit facility, and other market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Our cash requirements primarily consist of ~~the~~ principal and interest payments associated with our Senior Credit Facilities (as defined below), operating and finance leases, purchase commitments, and pension ~~obligations, contingent considerations and earn-outs.~~obligations. Such contractual obligations are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022. Through ~~September 30, 2022,~~March 31, 2023, we have not entered into any other material new or modified contractual obligations since December 31, ~~2021.~~2022.

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the ~~earnings~~operating income and the distribution of funds from our subsidiaries. ~~Local~~However, as local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to ~~us. There~~us, there is no assurance that ~~applicable laws and regulations and/or the terms of our indebtedness will permit~~ our subsidiaries will be permitted to provide us with sufficient dividends, distributions or loans when necessary.

As of ~~September 30, 2022, $57.7~~March 31, 2023, $56.0 million of our ~~$84.6~~$82.7 million cash and cash equivalents was held by subsidiaries outside of Canada and the U.S. Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions by those local subsidiaries and to pay down borrowings under our Senior Credit ~~Facilities (as defined below).~~Facilities. Approximately ~~$137.9~~$143.0 million of our outstanding term loan and revolver borrowings under our Senior Credit Facilities were held in our subsidiaries outside of Canada and the U.S. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries.

We deferred certain U.S. payroll tax payments in 2020 in accordance with relief provisions under the CARES Act. We paid $1.4 million of such deferred payroll tax payments in December 2021. As permitted under the CARES Act, we expect to pay the remaining $1.4 million of deferred U.S. Payroll taxes by December 31, 2022.

Senior Credit Facilities

In December 2019, we entered into the Third Amended and Restated Credit Agreement, originally consisting of a $100.0 million U.S. dollar equivalent euro-denominated (approximately €90.2 million) 5-year term loan facility ~~(approximately €90.2 million)~~ and a $350.0 million 5-year revolving credit facility (collectively, the “Senior Credit Facilities”). The Senior Credit Facilities ~~mature in~~had an original maturity date of December 2024 and included an uncommitted accordion option pursuant to which the commitments under the revolving credit facility may be increased by an additional $200.0 million in aggregate, subject to certain customary conditions. The term loan facility requires quarterly scheduled principal repayments of approximately €1.1 million beginning in March 2020 with the remaining principal balance due upon maturity. We may make additional principal payments at any time, which will reduce the next quarterly installment payment due. We may pay down outstanding borrowings under our revolving credit facility with cash on hand and cash generated from future operations at any time.

InOn March 27, 2020, we entered into an amendment (the “First Amendment”) to the Credit Agreement and exercised a portion of the uncommitted accordion option. The First Amendment increased the revolving credit facility commitment under the Credit Agreement by $145.0 million, from $350.0 million to $495.0 million, and reset the uncommitted accordion option to $200.0 million for potential future expansion.

On October 5, 2021, the Company entered into an amendment (the “Fourth Amendment”) to the Credit Agreement to exercise the accordion option. The Fourth Amendment increased the revolving credit facility commitment under the Credit Agreement by $200.0 million, from $495.0 million to $695.0 million, and reset the uncommitted accordion option to $200.0 million for potential future expansion.

On March 10, 2022, the Company entered into an amendment (the “Fifth Amendment”) to the Credit Agreement to extend the maturity date thereof from December 31, 2024 to March 10, 2027, update the pricing grid, replace LIBOR with SOFR as the reference rate for U.S. dollar borrowings, and increase the uncommitted accordion option from $200 million to $350 million.

As of ~~September 30, 2022,~~March 31, 2023, we had ~~$75.7~~$82.4 million term loan and ~~$372.3~~$345.6 million revolver borrowings outstanding under our Senior Credit Facilities. The borrowings outstanding under the Senior Credit Facilities bear interest at rates based on (a) the Base Rate, as defined in the Credit Agreement, plus a margin ranging between 0.00% and 0.75% per annum, determined by reference to our consolidated leverage ratio, or (b) the ~~Eurocurrency~~Term SOFR Loans, Alternative Currency Loans, and Letters of Credit Rate, as defined in the Credit Agreement, plus a margin ranging between 0.75% and 1.75% per annum, determined by reference to our consolidated leverage ratio. In addition, we are obligated to pay a commitment fee on the unused portion of the revolving credit facility, ranging between 0.20% and 0.30% per annum, determined by reference to our consolidated leverage ratio. As of ~~September 30, 2022,~~March 31, 2023, we had outstanding borrowings under the Credit Agreement denominated in Euro and U.S. Dollars of ~~$137.9~~$143.0 million and ~~$310.0~~$285.0 million, respectively.

The Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio (as defined in the Credit Agreement). The following table summarizes these financial covenants and our compliance therewith as of ~~September 30, 2022:~~March 31, 2023:


	Requirement		Actual		Requirement	Actual
Maximum consolidated leverage ratio (1)		3.50		2.33	3.50	2.14
Minimum consolidated fixed charge coverage ratio		1.50		8.89	1.50	6.74

(1)

Maximum consolidated leverage ratio shall be increased to 4.00 for four consecutive quarters following a designated acquisition, as defined in the Fifth Amendment.

Share Repurchase Plans

Our Board of Directors may approve share repurchase plans from time to time. Under these repurchase plans, shares may be repurchased at our discretion based on ongoing assessment of the capital needs of the business, the market price of our common shares, and general market conditions. Shares may also be repurchased through an accelerated share purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common shares to be repurchased when we would otherwise be prohibited from doing so under insider trading laws. While the share repurchase plans are generally intended to offset dilution from equity awards granted to our employees and directors, the plans do not obligate us to acquire any particular amount of common shares. No time limit is typically set for the completion of the share repurchase plans, and the plans may be suspended or discontinued at any time. We expect to fund share repurchases through cash on hand and cash generated from operations.

In October 2018, our Board of Directors approved a share repurchase plan (the “2018 Repurchase Plan”) authorizing the repurchase of $25.0 million worth of common shares. Share repurchases have been made under the 2018 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934. We completed the 2018 Repurchase Plan in the second quarter of 2022 and repurchased 80 thousand shares for an aggregate purchase price of $9.5 million at an average price of $118.97 per share. Since the inception of the 2018 Repurchase Plan, we have repurchased a cumulative total of 264 thousand shares at an average price of $94.57 per share.

In February 2020, our Board of Directors approved a new share repurchase plan (the “2020 Repurchase Plan”) authorizing the repurchase of an additional $50.0 million worth of common shares. Share repurchases have been made under the 2020 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934. ~~During~~The Company did not repurchase any shares during the ~~nine~~three months ended ~~September 30, 2022, we repurchased 4 thousand shares for an aggregate purchase price of $0.5 million at an average price of $116.95 per share under the 2020 Repurchase Plan.~~March 31, 2023. As of ~~September 30, 2022,~~March 31, 2023, we had $49.5 million available for share repurchases under the 2020 Repurchase Plan.

Cash Flows for the ~~Nine~~Three Months Ended ~~September 30,~~March 31, 2023 and April 1, 2022 ~~and October 1, 2021~~

The following table summarizes our cash flows, cash and cash equivalents, and unused and available funds under our revolving credit facility for the periods indicated (in thousands):


	Nine Months Ended						Three Months Ended
	September 30,			October 1,			March 31,			April 1,
	2022			2021			2023			2022
Net cash provided by operating activities	$	50,167		$	65,912		$	10,245		$	11,347
Net cash used in investing activities	$	(38,283	)	$	(302,140	)	$	(3,620	)	$	(6,821	)
Net cash used in financing activities	$	(36,669	)	$	214,290		$	(25,066	)	$	(22,029	)

	September 30,			December 31,			March 31,			December 31,
	2022			2021			2023			2022
Cash and cash equivalents	$	84,580		$	117,393		$	82,676		$	100,105
Unused and available funds under the revolving credit facility	$	322,713		$	348,421		$	349,410		$	336,587

Operating Cash Flows

Cash provided by operating activities was ~~$50.2~~$10.2 million for the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, versus ~~$65.9~~$11.3 million for the prior year period. Cash provided by operating activities for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 decreased from the prior year period primarily due to ~~a $46.6 million increase in inventories driven by increased customer demand and~~ higher critical raw material purchases, a $34.4 million increase in accounts receivable primarily driven by increased revenue, and a bonus payout in 2022 of $8.4 million compared to no bonus payout in 2021 as a result of the elimination of our 2020 annual bonus plan,incentive compensation payments, partially offset by ~~an increase in profit before tax from higher revenue.~~better net working capital performance versus the prior year period.

Beginning in January 2022, the Tax Cuts and Jobs Act of 2017 (“TCJA”) requires R&D expenditures be capitalized and amortized for income tax purposes over five years for domestic research and fifteen years for foreign research, rather than being deducted as incurred. This has the effect of increasing our cash taxes and deferred tax assets. If this provision under the TCJA is not deferred, modified, or repealed with retroactive effect going back to January 1, 2022, our operating cash flows are expected to decrease by approximately $9.2 million for the year ending December 31, 2022.

Investing Cash Flows

Cash used in investing activities was ~~$38.3~~$3.6 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2023, all related to capital expenditures.

Cash used in investing activities was $6.8 million for the three months ended April 1, 2022, primarily driven by ~~the MPH acquisition. We paid cash consideration of $22.4 million, net of cash acquired. We also paid~~ capital expenditures of ~~$15.4~~$6.3 million and a contingent consideration payment of $1.5 million related to our 2016 asset acquisition of video signal processing and management ~~technologies during the nine months ended September 30, 2022.~~

Cash used in investing activities was $302.1 million for the nine months ended October 1, 2021, primarily driven by the ATI and SEM acquisitions. In connection with these acquisitions, we paid cash consideration of $285.2 million (net of cash acquired of $14.6 million) during the nine months ended October 1, 2021. We also paid capital expenditures of $14.8 million and a contingent consideration payment of $2.2 million related to our 2016 asset acquisition of video signal processing and management technologies during the nine months ended October 1, 2021.technologies.

We expect to use an aggregate of approximately ~~$20~~$25 million to ~~$25~~$30 million in ~~2022~~2023 for capital expenditures related to investments in new property, plant and equipment for our existing ~~businesses.~~businesses, which includes a significant one-time buildout project in the U.K. for our Solid State and Ultrafast Lasers products.

Financing Cash Flows

Cash used in financing activities was ~~$36.7~~$25.1 million for the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, primarily due to ~~$46.3 million of contingent consideration payments related to prior year acquisitions, $37.8~~$15.3 million of term loan and revolving credit facility repayments ~~$10.0~~and $9.6 million of ~~repurchases~~payroll tax payments upon vesting of ~~common stock, $9.6~~share-based compensation awards.

Cash used in financing activities was $22.0 million for the three months ended April 1, 2022, primarily due to $11.6 million of term loan and revolving credit facility repayments, $7.7 million of payroll tax payments upon vesting of share-based compensation awards, and ~~$2.5~~$2.1 million of debt issuance costs in connection with the Fifth Amendment, partially offset by $69.9 million of borrowings under our revolving credit facility used to fund the contingent consideration paid for the ATI acquisition and cash consideration paid for the MPH acquisition.

Cash provided by financing activities was $214.3 million for the nine months ended October 1, 2021, primarily due to $280.0 million of borrowings under our revolving credit facility used to fund the cash considerations paid for the ATI and SEM acquisitions, partially offset by $30.7 million of payroll tax payments upon vesting of share-based compensation awards, $24.0 million of term loanAmendment.

and revolver credit facility repayments, $8.7 million payment for the purchase of a building under a finance lease agreement, and $1.8 million of contingent consideration payments related to acquisitions.

Critical Accounting Policies and Estimates

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this periodic report on Form 10-Q are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022. There have been no material changes to our critical accounting policies and estimates through ~~September 30, 2022~~March 31, 2023 from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Recent Accounting Pronouncements

~~See Note 1 to Consolidated Financial Statements.~~None.

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk

Our primary market risk exposures are foreign currency exchange rate fluctuations and interest rate sensitivity. During the three months ended ~~September 30, 2022,~~March 31, 2023, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of ~~September 30, 2022,~~March 31, 2023, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of ~~September 30, 2022.~~March 31, 2023.

Changes in Internal Control ~~over~~Over Financial Reporting

There has been no change to our internal control over financial reporting during the fiscal quarter ended ~~September 30, 2022~~March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

4335

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of these claims will have a material adverse effect upon its financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon its financial condition or results of operations.

Item 1A. Risk Factors

The Company’s risk factors are described in Part I, Item 1A, “Risk Factors”, of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021. There have been no material changes in our risk factors as included~~2022. The risks described in our Annual ~~Report.~~Report on Form 10-K for the fiscal year ended December 31, 2022 are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial position, or future results of operations. The risk factors set forth below update, and should be read together with, the risk factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Our results of operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and levels of business activities.

A large portion of our product sales are dependent on our customers’ need for increased capacity, productivity and cost saving initiatives, improved product quality and performance, and new investments. Weaknesses in our end markets could negatively impact our revenue and gross margin and consequently have a material adverse effect on our business, financial condition and results of operations. A severe and/or prolonged overall economic downturn or a negative or uncertain political climate could lead to weaknesses in our end markets and adversely affect our customers’ financial condition and the timing or levels of our customers’ capital expenditures or business activities. We have experienced significant cyclical end market fluctuations in the past. For example, diminished growth expectations, economic and political uncertainty in regions across the globe and effects of the COVID-19 pandemic adversely impacted our customers’ financial condition and ability to maintain product order levels and reduced the demand for our products in 2020. In addition, certain sub-segments of the advanced industrial market that we serve, including the microelectronics and industrial capital equipment sectors, are cyclical and have historically experienced periods of oversupply, resulting in downturns in demand for capital equipment in which many of our products are used. It is difficult to predict the timing, length and severity of these downturns and their impact on our business. Further, our order levels or results of operations for a given period may not be indicative of order levels or results of operations for subsequent periods. For the foreseeable future, our operations will continue to depend upon industries that are subject to market cycles which, in turn, could adversely affect the market demand for our products.

We have also faced increases in inflationary conditions in materials and components as well as labor costs, and we expect these inflationary conditions to continue in 2023. These inflationary conditions have caused us to increase prices; however, such price increases may not be accepted by our customers or may not adequately offset the increases in our costs, thereby negatively affecting our results of operations. Changes in global economic conditions, including inflationary conditions, could also shift market demand to products or services for which we do not have competitive advantages. This could negatively affect the amount of business that we are able to obtain. In addition, if we are unable to successfully anticipate changes in economic and political conditions, we may be unable to effectively plan for and respond to those changes, and our business could be negatively affected.

Adverse developments that affect financial institutions, transactional counterparties, or other third parties, or concerns or rumors about these events, have in the past and may in the future lead to market-wide liquidity problems. Uncertainty may remain over liquidity concerns in the broader financial services industry, and there may be unpredictable impacts to our business and our industry.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not repurchase any of its common shares during the three months ended September 30, 2002. For additional information regarding the Company's 2020 Repurchase Plan, see Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operation" above under the heading "Share Repurchase Plans."None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

4437

Item 6. Exhibits

Incorporated by Reference
Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed/
Furnished
Herewith

3.1

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999

S-3

333-202597

3.1

03/09/2015

3.2

By-Laws of the Registrant, as amended

10-K

001-35083

3.2

03/01/2021

3.3

Articles of Reorganization of the Registrant, dated July 23, 2010

8-K

000-25705

3.1

07/23/2010

3.4

Articles of Amendment of the Registrant, dated December 29, 2010

8-K

000-25705

3.1

12/29/2010

3.5

Articles of Amendment of the Registrant, dated May 11, 2016

8-K

001-35083

10.1

05/12/2016

3.6

Articles of Amendment of the Registrant, dated April 29, 2022

10-Q

001-35083

3.6

05/10/2022

10.1

Employment Agreement, dated July 11, 2022, between Novanta Inc. and Michele Welsh

10-Q

001-35083

10.1

08/09/2022

31.1

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

*

31.2

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

*

32.1

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**

32.2

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**

101.INS

Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

*

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

*

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

*

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

*

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

*

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Filed/

Furnished
Herewith

3.1

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999

S-3

333-202597

3.1

03/09/2015

3.2

By-Laws of the Registrant, as amended

10-K

001-35083

3.2

03/01/2021

3.3

Articles of Reorganization of the Registrant, dated July 23, 2010

8-K

000-25705

3.1

07/23/2010

3.4

Articles of Amendment of the Registrant, dated May 26, 2005

10K

001-35083

3.4

3/1/2023

3.5

Articles of Amendment of the Registrant, dated December 29, 2010

8-K

000-25705

3.1

12/29/2010

3.6

Articles of Amendment of the Registrant, dated May 11, 2016

8-K

001-35083

10.1

05/12/2016

3.7

Articles of Amendment of the Registrant, dated April 29, 2022

10-Q

001-35083

3.6

05/10/2022

10.1

Form of Grant Notice and Award Agreement for Performance Stock Unit Awards with rTSR Modifier

31.1

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith

** Furnished herewith

4538

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Novanta Inc. (Registrant)


Name	Title	Date

/s/ Matthijs Glastra	Chair of the Board of Directors and Chief Executive Officer	~~November 8, 2022~~May 9, 2023
Matthijs Glastra

/s/ Robert J. Buckley	Chief Financial Officer	~~November 8, 2022~~May 9, 2023
Robert J. Buckley

4639


New Brunswick, Canada		98-0110412
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

125 Middlesex Turnpike, Bedford, Massachusetts, USA		01730
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, no par value	NOVT	The Nasdaq Global Select Market


Item No.		Page No.

PART I — FINANCIAL INFORMATION		1

ITEM 1.	FINANCIAL STATEMENTS	1

	CONSOLIDATED BALANCE SHEETS (unaudited)	1

	CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)	2

	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)	3

	CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)	4

	CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)	5

	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	6

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	3025

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	4335

ITEM 4.	CONTROLS AND PROCEDURES	4335

PART II — OTHER INFORMATION		4436

ITEM 1.	LEGAL PROCEEDINGS	4436

ITEM 1A.	RISK FACTORS	4436

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	4436

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	4436

ITEM 4.	MINE SAFETY DISCLOSURES	4437

ITEM 5.	OTHER INFORMATION	4437

ITEM 6.	EXHIBITS	4538

SIGNATURES		4639


	September 30,			December 31,			March 31,			December 31,
	2022			2021			2023			2022
ASSETS
Current assets
Cash and cash equivalents	$	84,580		$	117,393		$	82,676		$	100,105
Accounts receivable, net of allowance of $741 and $556, respectively		144,633			115,617
Accounts receivable, net of allowance of $1,174 and $995, respectively								141,472			137,697
Inventories		162,807			125,657			166,671			167,997
Prepaid income taxes and income taxes receivable		994			1,997			1,669			1,508
Prepaid expenses and other current assets		14,721			13,161			12,305			13,212
Total current assets		407,735			373,825			404,793			420,519
Property, plant and equipment, net		95,030			87,439			103,967			103,186
Operating lease assets		43,520			48,338			41,964			43,317
Deferred tax assets		11,538			12,206			18,201			15,113
Other assets		5,543			5,586			5,542			4,414
Intangible assets, net		179,113			220,989			168,828			175,766
Goodwill		465,052			479,500			482,520			478,897
Total assets	$	1,207,531		$	1,227,883		$	1,225,815		$	1,241,212
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current portion of long-term debt	$	4,366		$	5,097		$	4,904		$	4,800
Accounts payable		79,577			68,514			66,009			75,225
Income taxes payable		7,822			4,514			14,479			13,660
Current portion of operating lease liabilities		7,663			7,334			7,657			7,793
Accrued expenses and other current liabilities		58,629			98,479			49,304			63,044
Total current liabilities		158,057			183,938			142,353			164,522
Long-term debt		438,447			429,361			418,535			430,662
Operating lease liabilities		40,907			45,700			39,578			40,808
Deferred tax liabilities		16,519			33,738			16,977			17,194
Income taxes payable		5,153			4,217			4,516			4,355
Other liabilities		6,246			9,638			5,839			6,085
Total liabilities		665,329			706,592			627,798			663,626
Commitments and contingencies (Note 15)
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred shares, no par value; Authorized shares: 7,000; No shares issued and outstanding		—			—			—			—
Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 35,689 and 35,601, respectively		423,856			423,856
Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 35,802 and 35,711, respectively								423,856			423,856
Additional paid-in capital		51,951			53,768			52,020			55,155
Retained earnings		115,322			56,533			148,849			130,584
Accumulated other comprehensive loss		(48,927	)		(12,866	)		(26,708	)		(32,009	)
Total stockholders' equity		542,202			521,291			598,017			577,586
Total liabilities and stockholders’ equity	$	1,207,531		$	1,227,883		$	1,225,815		$	1,241,212


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 30,			October 1,			September 30,			October 1,			March 31,		April 1,
	2022			2021			2022			2021			2023		2022
Consolidated net income	$	22,490		$	13,603		$	58,789		$	36,577		$	18,265	$	18,820
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax (1)		(18,972	)		(3,248	)		(37,672	)		(3,602	)		5,230		(4,772	)
Pension liability adjustments, net of tax (2)		710			448			1,611			832			71		313
Total other comprehensive income (loss)		(18,262	)		(2,800	)		(36,061	)		(2,770	)		5,301		(4,459	)
Total consolidated comprehensive income	$	4,228		$	10,803		$	22,728		$	33,807		$	23,566	$	14,361


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
			Emerging growth company	☐


	Common Shares					Additional Paid-In			Retained		Accumulated Other Comprehensive
	# of Shares			Amount		Capital			Earnings		Loss			Total

	Three Months Ended September 30, 2022
Balance at July 1, 2022		35,623		$	423,856	$	46,146		$	92,832	$	(30,665	)	$	532,169
Consolidated net income		—			—		—			22,490		—			22,490
Common shares issued under stock plans		67			—		—			—		—			—
Common shares withheld for taxes on vested stock awards		(1	)		—		(149	)		—		—			(149	)
Repurchases of common shares		—			—		—			—		—			—
Share-based compensation		—			—		5,954			—		—			5,954
Other comprehensive income (loss), net of tax		—					—			—		(18,262	)		(18,262	)
Balance at September 30, 2022		35,689		$	423,856	$	51,951		$	115,322	$	(48,927	)	$	542,202

	Nine Months Ended September 30, 2022
Balance at December 31, 2021		35,601		$	423,856	$	53,768		$	56,533	$	(12,866	)	$	521,291
Consolidated net income		—			—		—			58,789		—			58,789
Common shares issued under stock plans		238			—		—			—		—			—
Common shares withheld for taxes on vested stock awards		(66	)		—		(9,626	)		—		—			(9,626	)
Repurchases of common shares		(84	)		—		(10,000	)		—		—			(10,000	)
Share-based compensation		—			—		17,809			—		—			17,809
Other comprehensive income (loss), net of tax		—			—		—			—		(36,061	)		(36,061	)
Balance at September 30, 2022		35,689		$	423,856	$	51,951		$	115,322	$	(48,927	)	$	542,202

	Three Months Ended October 1, 2021
Balance at July 2, 2021		35,489		$	423,856	$	52,243		$	29,176	$	(12,211	)	$	493,064
Consolidated net income		—			—		—			13,603		—			13,603
Common shares issued under stock plans		199			—		—			—		—			—
Common shares withheld for taxes on vested stock awards		(88	)		—		(12,244	)		—		—			(12,244	)
Share-based compensation		—			—		8,490			—		—			8,490
Other comprehensive income (loss), net of tax		—			—		—			—		(2,800	)		(2,800	)
Balance at October 1, 2021		35,600		$	423,856	$	48,489		$	42,779	$	(15,011	)	$	500,113

	Nine Months Ended October 1, 2021
Balance at December 31, 2020		35,163		$	423,856	$	58,992		$	6,202	$	(12,241	)	$	476,809
Consolidated net income		—			—		—			36,577		—			36,577
Common shares issued under stock plans		658			—		—			—		—			—
Common shares withheld for taxes on vested stock awards		(221	)		—		(30,672	)		—		—			(30,672	)
Share-based compensation		—			—		20,169			—		—			20,169
Other comprehensive income (loss), net of tax		—			—		—			—	$	(2,770	)		(2,770	)
Balance at October 1, 2021		35,600		$	423,856	$	48,489		$	42,779	$	(15,011	)	$	500,113


~~Standard~~	~~Description~~	~~Effective Date~~	~~Effect on the Financial Statements or Other Significant Matters~~
~~In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.”~~	~~ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met.~~	~~Upon issuance. Adoption of ASU 2020-04 is elective.~~	In March 2022, the Company amended the Third Amended and Restated Credit Agreement and replaced LIBOR with SOFR as the new reference rate for U.S. dollar borrowings. The ASU did not have any impact on the Company’s consolidated financial statements.
~~In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.”~~	ASU 2021-08 requires that entities recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606, “Revenue from Contracts with Customers”. ASU 2021-08 also applies to contract assets or liabilities from other contracts to which the provisions of ASC 606 apply. The amendments in ASU 2021-08 do not affect the accounting for other assets or liabilities that may arise from revenue contracts with customers in accordance with ASC 606, such as refund liabilities, or in a business combination, such as customer-related intangible assets and contract-based intangible assets.	~~January 1, 2023. Early adoption is permitted.~~	~~The Company early adopted ASU 2021-08 as of January 1, 2022. The adoption of ASU 2021-08 did not have any material impact on the Company’s consolidated financial statements.~~


	Purchase Price
	Allocation
Cash	$	182
Accounts receivable		1,658
Inventories		957
Property, plant and equipment		12,094
Goodwill		9,863
Other assets		163
Total assets acquired		24,917
Accounts payable		562
Deferred tax liabilities		1,124
Other liabilities		664
Total liabilities assumed		2,350
Total assets acquired, net of liabilities assumed		22,567
Less: cash acquired		182
Purchase price, net of cash acquired	$	22,385


	Total Accumulated									Total Accumulated
	Other			Cumulative			Pension			Other			Cumulative			Pension
	Comprehensive			Translation			Liability			Comprehensive			Translation			Liability
	Loss			Adjustments			Adjustments			Loss			Adjustments			Adjustments
Balance at December 31, 2021	$	(12,866	)	$	(5,753	)	$	(7,113	)
Balance at December 31, 2022										$	(32,009	)	$	(24,427	)	$	(7,582	)
Other comprehensive income (loss)		(36,363	)		(37,672	)		1,309			5,046			5,230			(184	)
Amounts reclassified from accumulated other comprehensive loss		302			—			302			255			—			255
Balance at September 30, 2022	$	(48,927	)	$	(43,425	)	$	(5,502	)
Balance at March 31, 2023										$	(26,708	)	$	(19,197	)	$	(7,511	)


			Quoted Prices in				Significant Other				Quoted Prices in				Significant Other
			Active Markets for		Significant Other		Unobservable				Active Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs				Identical Assets		Observable Inputs		Inputs
	Fair Value		(Level 1)		(Level 2)		(Level 3)		Fair Value		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	1,596	$	1,596	$	—	$	—	$	269	$	269	$	—	$	—
Prepaid expenses and other current assets:
Foreign currency forward contracts		1,521		—		1,521		—		140		—		140		—
	$	3,117	$	1,596	$	1,521	$	—	$	409	$	269	$	140	$	—
Liabilities
Accrued expenses and other current liabilities:
Contingent considerations - Current	$	113	$	—	$	—	$	113	$	127	$	—	$	—	$	127
Foreign currency forward contracts		794		—		794		—		68		—		68		—
Other liabilities:
Contingent considerations - Long-term		274		—		—		274		307		—		—		307
	$	1,181	$	—	$	794	$	387	$	502	$	—	$	68	$	434


	Amount
Balance at December 31, 2021	$	50,924
Payments		(48,725	)
Fair value adjustments		(1,382	)
Effect of foreign exchange rates		(430	)
Balance at September 30, 2022	$	387


Balance at beginning of the period	$	479,500		$	478,897
Goodwill acquired from acquisitions		9,863
Effect of foreign exchange rate changes		(24,311	)		3,623
Balance at end of the period	$	465,052		$	482,520


	Reportable Segment												Reportable Segment
	Photonics			Vision			Precision Motion			Total			Precision Medicine and Manufacturing			Medical Solutions			Robotics and Automation			Total
Goodwill	$	201,864		$	162,128		$	252,289		$	616,281		$	210,009		$	169,497		$	254,243		$	633,749
Accumulated impairment of goodwill		(102,461	)		(31,722	)		(17,046	)		(151,229	)		(102,461	)		(31,722	)		(17,046	)		(151,229	)
Total	$	99,403		$	130,406		$	235,243		$	465,052		$	107,548		$	137,775		$	237,197		$	482,520


	Reportable Segment												Reportable Segment
	Photonics			Vision			Precision Motion			Total			Precision Medicine and Manufacturing			Medical Solutions			Robotics and Automation			Total
Goodwill	$	214,564		$	160,675		$	255,490		$	630,729		$	208,387		$	167,891		$	253,848		$	630,126
Accumulated impairment of goodwill		(102,461	)		(31,722	)		(17,046	)		(151,229	)		(102,461	)		(31,722	)		(17,046	)		(151,229	)
Total	$	112,103		$	128,953		$	238,444		$	479,500		$	105,926		$	136,169		$	236,802		$	478,897


	September 30, 2022							December 31, 2021							March 31, 2023							December 31, 2022
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Amortizable intangible assets:
Patents and developed technologies	$	178,968	$	(125,375	)	$	53,593	$	189,609	$	(122,130	)	$	67,479	$	185,977	$	(136,336	)	$	49,641	$	184,589	$	(132,350	)	$	52,239
Customer relationships		215,274		(112,689	)		102,585		228,656		(104,386	)		124,270		223,854		(127,261	)		96,593		222,173		(121,527	)		100,646
Customer backlog		6,795		(6,795	)		—		6,862		(2,254	)		4,608
Trademarks and trade names		22,644		(12,736	)		9,908		23,976		(12,371	)		11,605		23,479		(13,912	)		9,567		23,311		(13,457	)		9,854
Amortizable intangible assets		423,681		(257,595	)		166,086		449,103		(241,141	)		207,962		433,310		(277,509	)		155,801		430,073		(267,334	)		162,739
Non-amortizable intangible assets:
Trade names		13,027		—			13,027		13,027		—			13,027		13,027		—			13,027		13,027		—			13,027
Totals	$	436,708	$	(257,595	)	$	179,113	$	462,130	$	(241,141	)	$	220,989	$	446,337	$	(277,509	)	$	168,828	$	443,100	$	(267,334	)	$	175,766


Year Ending December 31,	Cost of Revenue		Operating Expenses		Total		Cost of Revenue		Operating Expenses		Total
2022 (remainder of year)	$	3,186	$	5,242	$	8,428
2023		11,583		19,633		31,216
2023 (remainder of year)							$	9,137	$	15,366	$	24,503
2024		9,434		16,467		25,901		9,895		17,195		27,090
2025		8,041		13,931		21,972		8,379		14,547		22,926
2026		6,750		11,835		18,585		6,998		12,379		19,377
2027								4,239		9,983		14,222
Thereafter		14,599		45,385		59,984		10,993		36,690		47,683
Total	$	53,593	$	112,493	$	166,086	$	49,641	$	106,160	$	155,801




	Shares (In thousands)		Weighted Average Exercise Price
Outstanding as of December 31, 2021		60	$	14.13
Granted		40	$	135.86
Exercised		—	$	—
Forfeited or expired		—	$	—
Outstanding as of September 30, 2022		100	$	62.77
Exercisable as of September 30, 2022		60
Expected to vest as of September 30, 2022		40